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THE ROLE OF ADAPTIVE IMMUNITY IN CHRONIC HYPOXIA-INDUCED
PULMONARY HYPERTENSION

by

LEVI DAVID MASTON
B.S. BIOCHEMISTRY, NEW MEXICO STATE UNIVERSITY, 2007
DOCTOR OF PHILOSOPHY
BIOMEDICAL SCIENCES

ABSTRACT

Inflammation is a prominent pathologic feature in pulmonary arterial
hypertension as demonstrated by pulmonary vascular infiltration of inflammatory cells,
including T and B lymphocytes. However, the contribution of the adaptive immune
system is not well characterized in pulmonary hypertension (PH) caused by chronic
hypoxia (CH). Inflammatory cells, through various mechanisms, have the capability to
increase pulmonary vascular resistance in various disease states. CD4+ T cells have the
potential to play a significant role in the disease process initiated by hypoxia. CD4+ T
cells are largely responsible for orchestrating downstream immune processes and are
critical in focusing and amplifying inflammatory responses by other immune effector
cells. Actions of CD4+ T cells are essential for the full development of adaptive immune
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cytotoxicity and antibody production. CD4+ T cells are required for initiating and
maintaining inflammation, suggesting these cells could play an important role in the
pathogenesis of hypoxic PH. Therefore, we tested the hypothesis that CD4+ T cells,
specifically the CD4+, IL-17a+ TH17 cell subset, contribute to CH-induced PH.
We compared indices of PH resulting from CH (PB=380 mmHg; 3 wk) in wildtype (WT) mice and RAG1 knock-out (KO) mice (lack mature T and B cells). Separate
sets of mice were adoptively transferred with CD4+ or CD8+ T cells, or ex vivo polarized
TH17 cells prior to normoxic or CH exposure to evaluate the involvement of specific T
cell subsets. Sham-treated RAG1 KO mice were protected from PH as indicated by
diminished right ventricular systolic pressure (RVSP) and arterial remodeling compared
to CH WT mice. Adoptive transfer of CD4+, but not CD8+ T cells, restored the PH
phenotype in RAG1 KO mice. Interestingly, RAG1 KO mice receiving TH17 cells
displayed evidence of PH independent of CH exposure. Further supporting our
hypothesis, depletion of CD4+ T cells or treatment with SR1001, an inhibitor of TH17 cell
development, prevented increased RVSP and arterial remodeling responses to CH.
Therefore, our data indicate that CD4+ T cells, specifically TH17 cells, contribute to CHinduced PH.
Interleukin-6 (IL-6) is a pleotropic cytokine that signals through the membranebound IL-6 receptor (mIL-6R) to induce anti-inflammatory (“classic-signaling”)
responses. This cytokine also binds to the soluble IL-6R (sIL-6R) to promote inflammation
(“trans-signaling”). mIL-6R expression is restricted to hepatocytes and immune cells.
However, activated T cells release sIL-6R into adjacent tissues to induce trans-signaling.
These cellular actions require the ubiquitously expressed membrane receptor gp130. IL-6
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is produced by pulmonary arterial smooth muscle cells (PASMCs) exposed to CH and IL6 knockout mice are protected from CH-induced PH. IL-6, through the activation of
STAT1 and STAT3 has the potential to contribute to a broad array of downstream effects,
such as cell growth and migration. CH-induced PH is associated with increased
proliferation and migration of PASMCs to previously non-muscularized vessels of the
lung. Therefore, we tested the hypothesis that IL-6 trans-signaling contributes to CHinduced PH and arterial remodeling.
Normoxic and CH (3 wk) mice were given the IL-6 trans-signaling-specific
inhibitor sgp130Fc, and indices of PH were measured. Plasma sIL-6R and sgp130 levels
were also measured in mice exposed to either normoxia or CH for 5 days. Additionally,
PASMC migration was evaluated using a scratch-wound healing assay and proliferation
assessed by measuring culture confluency over time and DNA incorporation of the
thymidine analog 5-ethynyl-2´-deoxyuridine (EdU). Plasma levels of sgp130 were
significantly decreased in mice exposed to CH for 5 days as compared to normoxic mice,
while sIL-6R levels were unchanged. Consistent with our hypothesis, sgp130Fc treatment
attenuated CH-induced increases in RVSP and pulmonary arterial remodeling as compared
to vehicle (saline)-treated mice. In addition, PASMCs cultured in the presence of IL-6 and
sIL-6R showed enhanced migration but not proliferation compared to those treated with
IL-6 or sIL-6R alone or in the presence of sgp130Fc. These results indicate that IL-6 transsignaling contributes to pulmonary arterial cell migration and CH-induced PH.
Although inflammation was previously believed to play little role in PH due to CH,
these findings indicate otherwise. From these studies we can conclude that the adaptive
immune system, through IL-6 trans signaling and TH17 cell polarization and recruitment,
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contribute to CH-induced PH. These mechanisms likely contribute to CH-induced PH
through enhanced PASMC migration, as seen when these cells are exposed to the T H17
cell-specific cytokine, IL-17, along with PASMC exposure to IL-6/sIL-6R complex.
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Chapter 1 – Introduction

Pulmonary Hypertension
Pulmonary hypertension (PH) is defined as mean pulmonary arterial pressure (mPAP)
greater than 25 mmHg at rest, which is typically determined by right heart catheterization. The
range for a normal pulmonary arterial systolic pressure is from 15 to 30 mmHg, with diastolic
pressure ranging from 4 to 12 mmHg and the normal mPAP less than 20 mmHg. Chronic
hypoxia (CH)-induced pulmonary hypertension (PH) (140) (Group III PH as defined by the
World Health Organization) is associated with residence at high altitude and respiratory diseases
such as chronic obstructive pulmonary disease (COPD), interstitial lung diseases, sleepdisordered breathing, obesity hypoventilation syndrome, and other conditions associated with
global airway hypoxia (98). Although PH results from a variety of processes, patients with PH
experience exercise limitations, exertional dyspnea, and in advanced cases right heart failure and
death (114). PH is a common complication of COPD and greatly affects the outcome of disease
(14). In patients with COPD, the level of PH is generally mild, yet is predictive of the patient’s
prognosis (108). To date, there has never been a clinical trial showing a sustained beneficial
effect of pulmonary vasodilators in these patients (120). A worsening of ventilation-perfusion
mismatch has been seen and is justification for why these medications are not used (7). There are
a variety of treatment options for patients with COPD, such as beta agonists, anticholinergics,
bronchodilators, and glucocorticoids. However, currently the only treatment for patients with
COPD and PH is supplemental oxygen, with several studies showing an improvement in
morbidity and mortality (103, 159). Therefore current medical regimens are limited to treating
the underlying lung disease and providing supplemental O2 (120).
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The role of the immune system and corresponding inflammation has been increasingly
recognized in various types of PH, such as idiopathic pulmonary arterial hypertension (IPAH)
and diseases associated with pulmonary arterial hypertension (PAH) such as connective tissue
disease and human immunodeficiency virus (HIV) infection. This is based on the observation
that there are increased circulating autoantibodies, such as antinuclear antibodies, and elevated
levels of circulating pro-inflammatory cytokines such as IL-1 and IL-6 (65) that are associated
with PAH. The role for inflammation and inflammatory cells in PH due to CH however, is less
well delineated.
Hypoxic pulmonary hypertension is usually characterized by mild to moderate pulmonary
vascular remodeling that is, for the most part, reversible, as compared to the progressively
worsening and irreversible PH seen in WHO Group I disease. While there are currently few
studies examining the role for inflammation in CH-induced PH, it is thought that inflammation,
particularly persistent inflammation, plays an important role. Studies looking at inflammation in
CH-induced PH have focused on the interactions between mesenchymal cells like fibroblasts and
smooth muscle cells, and leukocytes, like macrophages. The focus of our studies are the role of
the adaptive immune system and the cellular and molecular mechanisms leading to PH following
exposure to CH. Specifically we investigated the poorly studied role of CD4+, IL-17a+ T helper
17 (TH17) cells along with the contribution of the pleotropic cytokine interleukin-6 (IL-6) to CHinduced PH. Given the lack of current, effective therapy, we feel that elucidating the cellular and
molecular contribution of T cells to CH-induced PH can improve patient morbidity and
mortality.
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Enhanced Vasoconstriction
CH results in enhanced vasoconstriction (13, 18, 30, 31, 116) and vascular arterial
remodeling (149), polycythemia and inflammation. These changes lead to increased pulmonary
vascular resistance according to Poiseuille’s law which states that the resistance to flow (Q) of
fluid is related to a number of factors, including: the viscosity () of the fluid and the length (L)
and radius (r) of the tubing. Therefore, we can understand the effects of these changes with
respect to changes in pulmonary vascular resistance using the formula: 8L/πr4 which ideally
applies to rigid, straight tubing and laminar flow, yet allows us to make accurate approximations
for factors that determine resistance to flow given changes to the other hemodynamic
components listed above. Given that normal pulmonary arterial pressure is less than 25 mmHg at
rest, the pulmonary circulation is generally a low pressure, low resistance vascular bed.
However, during conditions such as COPD and other diseases that result in global airway
hypoxia, there are structural and functional changes that affect the vasculature such as enhanced
vasoconstriction. According to Poiseuille’s law, a decrease in vessel diameter due to
vasoconstriction results in an increase in vascular resistance. If we adapt Ohm’s law to fluid flow
and vascular pressure and resistance, any increase in vascular resistance leads to an increase in
vascular pressure. Therefore, any decrease in vessel diameter due to vasoconstriction results in
an increase in resistance and pressure. A variety of factors may lead to an increase in
vasoconstriction in the pulmonary circulation. These include vasoconstriction due to acute
hypoxia (hypoxic pulmonary vasoconstriction (HPV)), enhanced vasoconstriction to agonists and
enhanced basal arterial, or myogenic, tone (Figure 1).
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Figure 1. Schematic showing the major contributing factors to chronic hypoxiainduced pulmonary hypertension. Chronic hypoxia leads to fixed vascular
changes such as remodeling, including a decreased compliance of the vessels.
Chronic hypoxia simultaneously leads to an enhanced vasoconstrictor response,
while also leading to increases in blood viscosity (polycythemia) and thereby
increasing pulmonary arterial vascular resistance. The result is pulmonary
hypertension, and ultimately right ventricular hypertrophy and pulmonary heart
disease called cor pulmonale.
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A consequence of exposure to CH, as previously mentioned is HPV. Initially identified
by Bradford and Dean (16) and further characterized by Euler and Liljestrand (41), HPV
represents the intrinsic mechanism of the lungs for matching perfusion to ventilation. Matching
perfusion to ventilation is crucial for optimal function of the lung by delivering blood to areas of
the lung receiving adequate ventilation, thereby reducing the flow of blood to lung sections in
which O2 exchange is limited due to a variety of causes, such as disease, fibrosis and atelectasis.
Upon exposure to hypoxia, HPV happens quite rapidly, and reaches peak vasoconstriction within
minutes. HPV is sustained during hypoxia, but upon restoration of normal oxygen levels, HPV is
reversible. However, following long standing hypoxia leading to pulmonary hypertension and
vascular remodeling, HPV is impaired (36).
Interestingly, HPV is not activated when the lungs are perfused with hypoxic blood yet
ventilated with normoxic alveolar oxygen tension, but specifically by a decreased airway PO2
(35). Current research indicates that the sensor of low molecular oxygen that triggers HPV is the
mitochondria (61). The mitochondrion is a cellular organelle which originated as prokaryotic
endosymbionts that have evolved with eukaryotic cells for billions of years (50). They serve as
the cellular energy source, converting pyruvate from glycolysis into ATP. Electrons from
pyruvate flow down a redox gradient, ending at molecular oxygen. The energy extracted from
this transfer of electrons results in protons being transported across the inner mitochondrial
membrane. This buildup of hydrogen ions across this membrane generates the electrochemical
gradient needed to power a H+ transporter, the ATPase complex, which results in ATP synthesis.
Nearly two decades ago, Paul Schumacher and his student, Navdeep Chandel, discovered
that in cultured cells hypoxia resulted in the mitochondrial production of reactive oxygen species
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(ROS) (22). Although somewhat paradoxical that low O2 levels might lead to an increase in
ROS, the increase in ROS may be due to a disruption of respiration caused by hypoxia, found to
be specifically associated with complex III of the electron transport chain (22). Conversely, work
out of Jason Yuan’s laboratory has demonstrated a decrease in pulmonary arterial smooth muscle
cell (PASMC) ROS levels following acute (5-10 minutes) hypoxia, yet an increase in ROS levels
following chronic exposure to hypoxia (48 hours) (161). Some groups have even suggested that
there is not a change in ROS following hypoxia (42). From these observations it has been
elucidated that ROS plays a central role in HPV, although the exact mechanism is still debated.
Hypoxia decreases the activity of KV in pulmonary artery smooth muscle cells (8). The resulting
depolarization leads to an increase in intracellular Ca2+ concentration, and ultimately pulmonary
artery vasoconstriction.

Calcium-Dependent Vasoconstriction
Vascular smooth muscle, like all smooth muscle, maintains the ability to contract or relax
in response to a variety of stimuli in order to regulate both the volume of the blood vessel and the
local blood pressure. Thus, the primary function of vascular smooth muscle is to regulate the size
of the blood vessel lumen. Vascular smooth muscle cells (VSMC), like all other muscle cells, use
an increase in cytosolic Ca2+ to initiate contraction. VSMC have a variety of mechanisms to alter
intracellular Ca2+ levels. These mechanisms differ in their spatial and temporal distribution, and
range from cell-wide changes in Ca2+ to highly localized Ca2+ entry or release events (5). Ca2+
can enter the cell from extracellular sources, or be released from the sarcoplasmic reticulum, the
primary intracellular Ca2+ store of VSM cells. Ca2+ can be released from the sarcoplasmic
reticulum through the binding of ligands to G-protein coupled receptors (Gq), resulting in the
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production of diacylglycerol (DAG) and inositol 1, 4,5-triphosphate (IP3) which diffuses through
the cytosol to bind IP3 receptors on the sarcoplasmic reticulum, releasing calcium into the
cytosol. Extracellular Ca2+ influx is primarily mediated via the opening of voltage-dependent Ltype Ca2+ channels, however other channels such as transient receptor potential (TRP) cation
channels also mediate Ca2+ influx. VSMC express a high number of L-type Ca2+ channels on
their surface. These channels have the greatest influence on global intracellular Ca2+ levels, as
compared to other channels, and therefore their activity largely determines the VSMC’s
contractile state and vessel diameter (80).
VSMC contraction is accomplished through the activity of smooth muscle myosin, which
differs from skeletal and cardiac myosins in that it requires phosphorylation of Ser 19 of the
regulatory light chain to cause contraction. The phosphorylation of smooth muscle myosin is
accomplished by the Ser/Thr kinase called myosin light chain kinase (MLCK) (67). MLCK is a
calcium/calmodulin-dependent kinase that is activated by elevated levels of Ca2+. Calcium
activates this complex, activating MLCK, resulting in the phosphorylation of Ser 19 on MLC,
initializing actin/myosin interaction and the shortening of the contractile apparatus (152).
Interestingly, smooth muscle myosin will hydrolyze ATP in the presence of actin, albeit very
slowly; however, after phosphorylation of the 20-kDa regulatory myosin light chain, the rate of
hydrolysis is increased nearly 1000-fold due to an increase in the rate of product release (38).
Therefore, changes in myosin light chain phosphorylation regulate smooth muscle contraction,
along with relaxation.
In lungs from rats exposed to CH, the pressor response to acute hypoxia is impaired,
whereas the pressor response to vasoconstrictor agonists such as angiotensin II and
prostaglandins is enhanced (92). This suggests that the reduced pressor response to acute hypoxia
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in chronically hypoxic rats may be the result of abnormalities in the mechanisms that couple
acute hypoxia to contraction of the pulmonary arterial smooth muscle cells.
Exposure to CH results in PASMC depolarization and an increase in intracellular Ca2+
(141). An associated decrease in voltage-dependent K+ channel expression (KV) and activity has
been examined as a potential cause (112, 117). Inhibition of K+ channel activity or expression
would result in decreased K+ current, leading to depolarization of the PASMC, activation of
voltage-gated calcium channels (VGCC) and an increase in intracellular Ca2+, leading to
PASMC constriction. This is supported by the findings that VGCC antagonists such as nifedipine
and verapamil attenuate CH-induced PH (44, 77).
Interestingly, studies have shown that the elevated resting intracellular Ca2+ levels
measured in PASMC from animals exposed to CH are unresponsive to nifedipine but reduced
instantaneously to the level of control PASMCs by removal of extracellular Ca2+, indicating that
there are other channels besides VGCC involved in Ca2+ influx associated with CH exposure
(137). In addition to VGCC, intracellular Ca2+ levels of PASMC are also affected by
nonselective cation channels. Studies have shown that transient receptor potential (TRPC)
channels represent store-operated and receptor-operated cation channels, and play an important
role in Ca2+ regulation and cell proliferation (60, 162). Furthermore, TRPC1 and TRPC6, are
upregulated following exposure to CH (88). PASMC have been shown to depend on increased
levels of intracellular Ca2+ for proliferation (111). It is thought that intracellular Ca2+ interacts
with Ca2+-responsive genes associated with cell growth, such as c-fos, through the actions of
calcium-binding protein (CBP) and cAMP response element-binding protein (CREB). Therefore,
because of a reduction in Kv channel expression and resulting activation of VGCC, and an
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increase in TRPC expression following CH, PASMC have the potential both have increased
contraction and proliferation.
The acid-sensing ion channel (ASIC) has mostly been studied in relation to neuronal
sensation of pain. Acid-stimulated cellular currents were initially observed in neurons in the
early 1980s (52, 84). ASIC channels are permeable to cations and are activated by extracellular
acidosis (84). Evidence from the last 10 years indicate that certain ASIC channels are expressed
in VSM cell (34) and within the VSM of pulmonary arteries (71). Studies from our group have
shown that ASIC1 contributes to pulmonary vascular smooth muscle store-operated Ca2+ entry
(113). Interestingly, HPV in isolated lungs from ASIC1(-/-) mice and indices of PH in ASIC1 (/-) mice were both attenuated as compared to WT control mice (70). These results clearly
demonstrate a role for ASIC1 in HPV and PH due to CH (102).
Interestingly, another molecule that has been shown to be important in the development
of CH-induced PH is the nuclear factor of activated T cells (NFAT). NFAT was originally
described in T cells, acting as a master regulator of multiple inflammatory mediators, leading to
the activation of T cells and the production of pro-inflammatory cytokines (90). Increased levels
of intracellular Ca2+ activate the phosphatase calcineurin, which dephosphorylates cytoplasmic
NFAT, allowing its entry to the nucleus, where it forms complexes with other transcription
factors (like GATA or activator protein-1) and regulates gene transcription (15). There are four
members of the NFAT family, with the NFATc3 isoform being specifically implicated in
vasculature development, maintenance of a contractile phenotype and regulation of vascular
smooth muscle cell contractility (31), and in CH-induced PH (13, 31). The NFATc3 isoform is
implicated in the maintenance of a contractile phenotype (49) and regulation of vascular smooth
muscle cell contractility (6, 31). Following exposure to CH, NFATc3 has been shown to be
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required for PASMC proliferation and re-differentiation (13, 31). Evidence from other groups
has demonstrated that another isoform of NFAT, NFATc2, has been implicated in the
pathogenesis of PAH in patients and in rats treated with monocrotaline (15). Activation of
NFATc2 leads to the downregulation of Kv1.5 and subsequent influx of calcium and thus
increased contraction and proliferation(111) and accumulation of intracellular potassium leading
to the suppression of apoptosis (119).

Calcium Sensitization
Mechanisms exist which increase the sensitivity of the contractile apparatus to
intracellular Ca2+ levels. In addition to MLCK, which phosphorylates and activates myosin, there
is another enzyme, myosin light chain phosphatase (MLCP), which dephosphorylates myosin.
Dephosphorylation of myosin by MLCP decreases the activity of myosin, and therefore, any
inhibition of MLCP activity will increase the activity of myosin. Therefore, PASMC contraction
is mediated by a balance between the actions of Ca2+/calmodulin, MLCK and MLCP (72). A
large number of pathways have been reported to inhibit MLCP, some associated with RhoAassociated protein kinase (ROCK)-dependent mechanisms (56). RhoA is a small GTPase of the
Ras superfamily which is activated following the stimulation of several G-protein-coupled
receptors (GPCR) (72). The binding of a GPCR ligand on the cell surface results in the activation
of guanine nucleotide exchange factors (GEFs) in the cytoplasm, which facilitate the exchange of
inactive GDP-bound RhoA for active GTP-bound RhoA. Once bound to GTP, RhoA translocates
from the cytosol to the membrane allowing for further interaction with downstream targets, such
as ROCK. Among the many targets of ROCK is MLCP, and therefore the RhoA/ROCK system
is a central player in vasoconstriction and dilation. The inactivation of MLCP allows for a greater
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contractile response for a given Ca2+ concentration. This phenomenon is called myofilament Ca2+
sensitization (72).
RhoA and its downstream effector ROCK play a crucial role in a variety of cellular
functions such as the previously mentioned smooth muscle contraction, but also cytoskeletal
rearrangement, cell migration, cell proliferation and gene expression (45, 66, 121, 143, 144). The
paradigm for CH-mediated increases in pulmonary arterial pressure has been that PH results
from hypoxia-induced structural changes in the vasculature, resulting in fixed increases in
resistance. The structural changes include remodeling of the artery walls leading to reduced
vascular lumen diameter, and a phenomenon of rarefaction or loss of blood vessels (62).
However, while investigating the role of Rho A and ROCK in CH-induced PH, Jean-Marc
Hyvelin et al (66) found evidence that CH does not result in a structural-based reduction in
lumen diameter, nor rarefaction. Their study demonstrated that the inhibition of ROCK
abrogated the development of hypoxic PH by inhibiting sustained pulmonary vasoconstriction
(66). Studies have shown that although Ca2+/calmodulin-dependent MLCK-mediated myosin
light chain phosphorylation is the key factor for triggering VSMC contraction, Ca2+ sensitization
is important for the sustained phase of contraction which contributes to CH-induced pulmonary
hypertension (143). In 2004, Nagaoka et al. demonstrated that ROCK is a major contributor to
CH-induced increases in pulmonary arterial pressure along with other indices of pulmonary
hypertension. They showed that Rho A/ROCK-mediated Ca2+ sensitization contributes
significantly to the increased pulmonary vascular tone and vasoreactivity present in pulmonary
hypertension (100). Interestingly, RhoA/ROCK is also required for NFATc3 activation following
CH, contributing to PASMC proliferation and re-differentiation to a more contractile phenotype,
contributing to enhanced vasoreactivity and tone (30).
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CH leads to an increase in PASMC intracellular reactive oxygen species (ROS) mostly
derived from NADPH oxidase. (33, 73, 105). Other sources of ROS include xanthine oxidase,
the mitochondrial respiratory chain, lipoxygenases and nitric oxide synthase (51, 115, 157). In
addition to being stimulated by GPCR, ligand binding studies have demonstrated that
RhoA/ROCK may be directly activated by superoxide anion (O2-.) (2). When the O2-. scavenger
tiron is used in arteries from rats exposed to CH, endothelin-1-induced vasoconstriction is largely
inhibited, indicating a central role for ROS in vasoreactivity, specifically in animals exposed to
CH (73).
It has been generally accepted that hypoxic pulmonary hypertension results from a
combination of sustained vasoconstriction and vascular remodeling. It is generally thought that
the contribution of vasoconstriction is greatest early in the disease process, and that structural
remodeling of the pulmonary vascular bed becomes progressively more important over time
(150).

Vascular Remodeling

Central to the pathology of pulmonary hypertension is the process of vascular
remodeling. Remodeling is largely mediated by structural and functional changes to the normal
architecture of the wall of the pulmonary arteries that lead to increased muscularization of the
already muscularized arteries, muscularization of the peripheral, or distal previously nonmuscularized arteries, the formation of neointima, and in pulmonary arterial hypertension, the
formation of plexiform lesions (151).
Animals exposed to CH demonstrate changes in pulmonary arterial structure (149). It has
been demonstrated for decades that exposure of animals to CH induces a rapid (2 days) alteration
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in the distribution of muscle cells in the vascular tree, in that there is the appearance of new
muscle in the non-muscular regions of the artery. Also, exposure to CH alone (people living at
high elevations) can result in increased pulmonary arterial pressure, only a small portion of
which can be reversed with the administration of supplemental O2 (9). Interestingly, this
muscularization is not necessarily an extension of muscle along the artery, but may also
represent the differentiation of new muscle from other cell types (94). The distal extension of
smooth muscle cells is quite specific to hypoxia-induced pulmonary hypertension, and is
demonstrated by the appearance of smooth muscle-like cells, as defined by the expression of
alpha-smooth muscle actin, in previously non-muscularized vessels. The medial thickening is not
only due to the increase in proliferation, but also to hypertrophy of existing smooth muscle cells,
along with an increased deposition of extracellular matrix proteins such as collagen and elastin.
Vascular adventitial thickening also affects the pulmonary arteries in response to CH, and is
mediated by the accumulation of fibroblasts and myofibroblasts, along with an increase in
extracellular matrix deposition (147).
In a variety of pathologic states, including CH-induced PH, endothelin-1 (ET-1)
production is increased, leading to elevated ET-1 plasma levels, along with elevated ET-1 levels
in the lungs (87). ET-1 is a 21-amino acid polypeptide produced primarily by endothelial cells.
ET-1 is a member of a family of structurally related peptide hormones and is the most potent
endogenously produced vasoconstrictor known (125). ET-1 binds to endothelin A (ETA) and ETB
receptors on PASMC to cause an increase in intracellular Ca2+ and vasoconstriction (46, 73,
163). Studies have shown that animals exposed to CH have increased production of ET-1,
leading to PASMC proliferation, migration, and cell survival (69, 93, 166). Also, studies have
demonstrated the contribution of ET-1 to CH-induced PH through the use of ET receptor
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antagonists such as bosentan to prevent and reverse hypoxic pulmonary hypertension in rats (26).
ROS such as O2-. and hydrogen peroxide (H2O2) have been implicated in the proliferation of
PASMCs. Studies have shown that ROS can increase ET-1 production, which can then lead to
increased levels of intracellular Ca2+ along with protein kinase C (PKC), phospholipase C (PLC),
phosphoinositide 3-kinase (PI3K), associated with ERK1/2 activation, resulting in cell
proliferation, migration, and survival (29,151).

Polycythemia

Polycythemia is a condition in which the proportion of blood volume that is occupied by
red blood cells increases. Blood volume proportions are measured as hematocrit, and during
polycythemia, a hematocrit of >55% is typical. The production of red blood cells, called
erythropoiesis, is regulated by erythropoietin (EPO) which is largely produced in the kidneys and
liver, with lower levels proving to be crucial for brain development in the fetus and
neuroprotection in the adult brain (104). The hypoxic activation of EPO is a key example of O2dependent gene regulation, and the search for the transcription factor that regulates EPO led to
the discovery of hypoxia-inducible factor (HIF) (54).
HIF regulates a large variety of tissue-specific hypoxic responses. Specifically, HIF
regulates erythropoiesis at many levels, including renal and hepatic EPO synthesis (54). The
main site of renal EPO synthesis consists of peritubular interstitial fibroblasts, which are
typically found in the renal cortex and outer medulla (167). The kidney responds to hypoxia by
increasing the number of these EPO producing cells (83), which in turn produce more EPO
through hypoxic induction of gene transcription. During hypoxia, serum levels of EPO,
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depending on the severity of hypoxia, may increase up to several hundred fold (37). HIF is a
heterodimeric basic helix-loop-helix transcription factor that consists of an O2-sensitive αsubunit and a constitutively expressed β-subunit. There are three known α subunits, HIF-1α,
HIF-2α and HIF-3α. Under normoxic conditions, all three HIF α-subunits are rapidly degraded
following ubiquitination, which requires hydroxylation of proline residues on HIF-α itself. O2dependent enzymes called HIF 2OG oxygenases, which require molecular O2 for catalysis, carry
out the hydroxylation of specific proline residues. Therefore, under hypoxic conditions,
hydroxylation is inhibited and HIF levels increase, and HIF forms complexes with transcriptional
coactivators which bind DNA, leading to the production of EPO and resultant polycythemia.

Immune System Contribution to Chronic Hypoxia Induced Pulmonary Hypertension

Immune System Overview
To understand the potential role of the immune system in the pathogenesis of pulmonary
hypertension, it is important to have at least a basic understanding of the cells and mechanisms
involved. The basic function of the immune system is the detection of foreign pathogens, such as
bacteria and viruses, and to protect the host from the associated diseases. The immune system
can broadly be separated into two major subsets, innate and adaptive with overlapping yet
distinct effector mechanisms of pathogen recognition and clearance.
The innate immune system responds nonspecifically, and rapidly, and is considered to be
the first line of defense against all foreign pathogens. The innate immune system consists of
cells, such as macrophages, dendritic cells, natural killer cells, etc. along with circulating
proteins, such as the complement system (12). Macrophages represent an important cell type of
the innate immune system, in that macrophages patrol and sample their environment, and express
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on their surface many innate immune receptors such as toll-like receptors (3). Importantly,
macrophages provide a crucial function for the activity of the other immune branch, the adaptive
immune system, by acting as antigen presenting cells (APC) (158). APCs, such as macrophages,
dendritic cells and B cells, patrol tissue or the circulation, or reside in lymph nodes, and
constantly sample their environment. This sampling is accomplished by the constant pinocytosis
or phagocytosis of their surroundings, processing the proteins and loading them into the major
histocompatibility complex II, where the peptide is then exposed on the cell surface, where it
interacts with circulating T lymphocytes, key players of the adaptive immune system (86). In
contrast to the non-specific and rapid response of the innate immune system, the response from
the adaptive immune system takes days to completely manifest. The adaptive immune response
is highly specific, and very importantly, has long lasting effects for future infections from the
same pathogen, called memory. Adaptive immunity can be broadly classified into two branches,
antibody-mediated (humoral) and cell-mediated (4). The humoral branch is mediated by the
activity of B lymphocytes, or B cells, and the cell-mediated branch is defined by the activity of T
lymphocytes, or T cells. T cells are the primary cell that interacts with the APCs, using their T
cell receptor to interact with the major histocompatibility complex (MHC) expressed on the
surface of the APC. T cells can be further divided into two main groups, the T helper cell (CD4+)
and the cytotoxic T cell (CD8+), which are defined by their expression of either CD4, which
interacts with MHC II on APCs or CD8, which interacts with MHC I found on all nucleated cells
of the host. There are three major types of T helper cell, including TH1, TH2 and TH17, and each
group is defined by their effector functions and what key cytokines they produce (68).
For T helper cell activation, two signals are required, which guide naïve T helper cells to
differentiate into specific TH subset. The first signal occurs when an antigen from an APC is
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presented on an MHC II protein, which is recognized by the T cell receptor, present on the T cell
surface. The second signal occurs with the interaction of the co-stimulatory molecule CD28 on
the APC and CD86 on the T cell. During these two simultaneous signaling events, the cytokines
expressed from the APC help to determine the TH subset of that T cell (68). For example, for the
naïve T cell to differentiate into a TH1 cell, they are exposed to the cytokine interleukin (IL)-12.
Once differentiated, that TH1 cell will produce several cytokines such as IFN, TNF-, IL6 and
IL-12, which are considered pro-inflammatory, TH1 cytokines. In contrast, exposure of TH2associated cytokines such as IL-4 drives T helper cells to produce IL-4, IL-10 and TGF-. These
TH2 cytokines promote the B cell-mediated production of antibodies. In 2005, a new subset of T
helper cells was described that was distinct from TH1 and TH2 cells. These cells are what we now
know as TH17 cells (55). Naïve T cells differentiate into TH17 cells upon exposure to IL-6, IL-23
and TGF-, which activate the transcription factor ROR, the master regulator for the TH17specific and eponymous cytokine family IL-17, along with other pro-inflammatory cytokines IL21 and IL-22 (91). Most studies looking at the specific role for TH17 cells show that their main
function is to recruit other cell types, such as neutrophils and macrophages, to injured or infected
tissue, especially mucosa, and therefore they act as early mediators of tissue injury and
inflammation (81).
There is also a type of T helper cell, which, in contrast to the other T helper subsets, provides an
anti-inflammatory response, suppressing the immune response to specific self and foreign
antigens. These are called regulatory T cells (Tregs) and are defined by their reliance on and
expression of the transcription factor FOXP3. These cells exert their effect likely through a cellcell interaction, along with the production of anti-inflammatory cytokines, such as IL-10 (126).
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Inflammation and Hypertension
The literature has many more studies examining the contribution of immune system
activation to systemic hypertension, as compared to pulmonary hypertension. Many studies have
been done to identify a pro-inflammatory environment in connection with elevated systemic
blood pressure, and because cytokines are good markers for immune activation and are readily
accessible biological markers (blood plasma), these studies are easy to find. In 2005, Bautista et
al. (11) examined blood samples from patients with hypertension, looking for pro-inflammatory
acute phase cytokines such as TNF-, IL-6, and C-reactive protein. The study found that in
patients with hypertension there were increased levels of plasma TNF-, and IL-6, as compared
to normotensive individuals. Interestingly, the association between inflammation and blood
pressure can be seen even in healthy volunteers. Even in normotensive individuals, there is a
direct association between plasma IL-6 levels and blood pressure (21). A major drawback to this
and many other human studies, however, is their inability to discern a cause-and-effect
relationship.
Evidence from both animal models and human studies indicate that inflammation
contributes to the development of pulmonary hypertension, with most studies dealing with PAH.
In lung biopsy samples taken from patients with PAH, immune cells are seen in conglomerates
called plexiform lesions, mainly consisting of T cells, macrophages and some B cells (28). There
is an increase in T cells in the pulmonary vasculature in lungs from patients with PAH. Some
studies have shown that cytotoxic CD8+ T cells constitute a major part of the inflammatory
component in plexiform lesions (130). In one study, T cell-deficient rats were more likely to
develop PAH, which likely has to do with a deficiency of regulatory T cells (Tregs) (153).
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Interleukin-6 and Trans-Signaling
IL-6 is a pro-inflammatory cytokine that is produced by T cells, macrophages, and
interestingly, muscle cells, so much so that it is also considered a myokine (97). The actions of
IL-6 are considered pleiotropic, in that they have a broad range of effects, across a variety of cell
types. IL-6 has been linked to many diseases including systemic and pulmonary vascular disease
(79). In addition to IL-6 levels being associated with hypertension and directly correlated with
blood pressure, IL-6 has been implicated in the pathogenesis of pulmonary hypertension.
IL-6 is a prominent member of a large group of cytokines which share a four-helical
structure. Members of the IL-6 family include IL-1, IL-27, IL-31 and many others (132). These
cytokines all share the membrane glycoprotein gp130 as a common receptor and signal
transduction subunit. IL-6 initially binds to the membrane bound  receptor, or IL-6R, and the
IL-6/IL-6R complex then associates with the protein gp130, inducing dimerization and initiating
downstream intracellular signaling via the JAK/STAT pathway (59). gp130, also known as
CD130, is expressed in almost all organs, including brain, kidney, spleen, liver, heart, and lung.
The targeted deletion of the gp130 gene in mice resulted in embryonic lethality at day 12 (164).
Further examination showed that these mice demonstrated hypoplastic ventricular myocardium
and greatly reduced numbers of hematopoietic progenitors in the liver and T cells in the thymus
(164). These findings show that gp130 plays a central role in development, hematopoiesis, cell
survival and growth. Initially, gp130 was thought to be the  subunit of the IL-6R, however it
also transmits signals for IL-11, IL-27, oncostatin-M, ciliary neurotrophic factor, cardiotrophin-1
and leukemia inhibitory factor (10, 32, 39, 40, 58, 82, 109, 110).
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Because of the pleiotropic nature of the gp130 subunit in downstream signaling, and its ability to
interact with many cytokines and growth factors, the cytokines which bind gp130 demonstrate a
degree of functional redundancy and specialization. gp130 has no affinity for IL-6 or the IL-6R
alone, and therefore, IL-6 can only bind and stimulate cells which express the IL-6R. However, a
major caveat to this “classical” IL-6 signaling has been described in which a soluble form of the
IL-6R has been detected in urine and blood (106). Soluble IL-6 receptor (sIL-6R) can be
generated through two mechanisms, the proteolytic cleavage of the surface receptor through the
actions of the metalloprotease ADAM17 (96) and by differential splicing of mRNA (89). This
alternative IL-6 signaling is called trans-signaling. Trans-signaling relies on the binding of IL-6
with the sIL-6R in solution, and this binary cytokine complex can then interact with gp130.
Trans-signaling greatly expands the repertoire of available IL-6-responsive cells, as gp130 is
expressed on the cell membrane of nearly all the cells in the body. Recent studies have
demonstrated that most of the pro-inflammatory and deleterious effects of IL-6, including the
generation of autoimmune TH17 cells and the inhibition of T cell apoptosis or proliferation of
malignant epithelial cells can be attributed to IL-6 trans-signaling (133). It appears that although
the two mechanisms of sIL-6R production both contribute to trans-signaling, the ectodomain
shedding of the transmembrane protein, as mediated by the metalloproteinase ADAM17, is the
main contributor towards the pro-inflammatory trans-signaling events (78). Studies have shown
that the receptor shedding mediated by ADAM17 is stimulated by exposure of T cells to
lipopolysaccharide (LPS) and treatment with phorbol 12-myristate 13-acetate (PMA) (136).
Ectodomain shedding is a regulated process that can be rapidly stimulated by signaling
events such as Ca2+ influx, activation of ERK, PKC, tyrosine kinases and via G-protein coupled
receptors. ADAM (a disintegrin and metalloproteinase) family of membrane-anchored
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metalloproteinases have been implicated in the activated shedding of many proteins, such as
EGFR-ligands, along with the previously mentioned sIL-6R. ADAM17, also known as TNF-
converting enzyme, responds rapidly to stimulation with PMA and the Ca2+ ionophore
ionomycin (47). Few studies have been done looking at the specific sources of the sIL-6R,
although secretion of sIL-6R has been reported by neutrophils, monocytic and hepatocytic cell
lines, and human T lymphotropic virus type I-transformed T cell lines (63)(76)(64). Recently
however, studies have confirmed that sIL-6R is produced by CD4+ T cells upon stimulation with
anti-CD3/CD28 antibodies, which mimic T cell activation (156). The production of sIL-6R from
activated CD4+ T cells was reliant upon the ADAM-dependent shedding of sIL-6R from the
membrane. The shedding of sIL-6R from CD4+ T cells appears to occur rapidly (within 60
minutes) of cell activation. These studies indicate that both naïve and memory CD4+ T cells are
capable of producing sIL-6R through membrane shedding, and that CD4+ T cells indeed
represent an additional and likely critical source of sIL-6R during an immune response (17).
Hypoxia induces the production of IL-6 from PASMC, as demonstrated by Savale et al.
in 2009 (131). When mice were exposed to CH, in this case 10% O2 in a ventilated chamber,
there was a rapid rise in total lung IL-6 mRNA and protein levels. These levels peaked at 24
hours and declined by day 7 and returned to basal levels after about 2 weeks of hypoxia
exposure. Immunostaining of lung sections demonstrated IL-6 staining specific to the pulmonary
arteries (131). The researchers found that the levels of IL-6R and gp130 mRNA were elevated in
whole lung as well.
As previously mentioned, IL-6 is required for the polarization of naïve CD4+ T cells to
the pro-inflammatory T helper subset, TH17. Patients with PAH have increased IL-6 serum
levels, which positively correlate with their prognosis (65, 145). Consistent with a role for IL-6
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in various forms of PH, IL-6 KO mice exposed to CH showed a decreased inflammatory cell
recruitment in the lungs, along with an attenuated increase in RVSP and decreased pulmonary
arterial remodeling, as compared to hypoxia-exposed WT mice (131). In addition, lung-specific
transgenic mice show spontaneous pulmonary hypertension, even in normoxic conditions, and
develop exaggerated pulmonary hypertension when exposed to CH (146). In addition to Savele,
Hashimoto-Kataoka et al. showed that hypoxia exposure leads to the increased expression of IL6 mRNA in the lungs. Patients with idiopathic pulmonary hypertension or pulmonary
hypertension associated with fibrotic diseases of the lung, such as scleroderma, have shown
increased levels of plasma IL-6 (65, 165)
In the last decade, a tool has been developed which greatly expands our ability to
differentiate between IL-6 classical signaling, and IL-6 trans-signaling (123, 124). The
extracellular portion of gp130 was created as an IgG1-Fc fusion protein, which is a gp130 dimer.
sgp130Fc, like sgp130, has been shown to selectively interact with sIL-6R in the presence of IL6 (76). Therefore, the sgp130 and the sgp130Fc protein inhibit IL-6 trans-signaling. Importantly,
sgp130Fc has been shown to not inhibit other gp130 cytokines such as ciliary neutrotrophic
factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM) and IL-27, making
sgp130Fc a specific inhibitor of IL-6 trans-signaling (134). Furthermore, the dimerization of
sgp130 as seen with the sgp130Fc, results in a 10-100 fold greater affinity for the IL-6/sIL-6R
complex.

T Helper 17 Cells
Many inflammatory diseases, such as rheumatoid arthritis are notable for their IL-6dependent accumulation of TH17 cells (154). As a pro-inflammatory cytokine, IL-6 organizes
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leukocyte trafficking and regulates the transition from innate to adaptive immunity by regulating,
in part, leukocyte activation, polarization and proliferation (74). When, in 2006, it was
discovered that IL-6 in combination with TGB- promote the differentiation of IL-17-producing
T helper cells, now known as TH17 cells, there was a renewed interest in IL-6 signaling. Initially,
it was thought that anti-IL-6 antibodies, such as tocilizumab could potentially prevent TH17associated pathologies of various autoimmune/chronic inflammatory states (75). Given the
dependence of TH17 cell development on IL-6, researchers examined the effects of hypoxia on
lung IL-17 levels, the signature cytokine of TH17 cells (57). Their studies showed that IL-17
mRNA in the lungs peaked on day 2 of hypoxic exposure and declined by day 7 while still
staying slightly elevated. IL-17a, while considered the signature cytokine for TH17 cells, it is also
expressed by other inflammatory cells. Therefore, they also looked at other TH17-associated
molecules, such as the retinoic acid receptor-related orphan receptor-c (RORt) and IL-17
downstream chemokines, such as Cxcl1 and Cxcl5, in the lungs of mice exposed to 2 days of
hypoxia. All these markers of TH17 cells were elevated in mice, and interestingly, when an
inhibitor of IL-6 was given (MR16-1, a rat anti-mouse IL-6 receptor antibody (107)), there was a
near complete inhibition of TH17 cell accumulation in the lung, further highlighting the
association between increased IL-6 levels following hypoxia, and the associated increase in TH17
cells. Crucially, this study also shows that the development of hypoxic pulmonary hypertension
was significantly attenuated in mice exposed to hypoxia receiving MR16-1, further strengthening
the connection between hypoxic pulmonary hypertension, IL-6 and TH17 cells.
IL-17a has been strongly implicated in the increased airway smooth muscle mass
associate with severe asthma. It was shown that IL-17 contributed to airways smooth muscle
proliferation and enhanced survival (decreased apoptosis) in vitro. This response was mediated
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directly by IL-17A’s effect on the IL-17A receptor, as specific blockade of the IL-17A receptor
abrogated this response (23). Similarly, an associated study demonstrated that IL-17 promote
airway smooth muscle cell migration in vitro, also mediated by direct effect of IL-17 on the IL17 receptor, as demonstrated by direct receptor antagonism with specific antibody (24). Although
there is evidence that airways smooth muscle cells share embryologic origin with pulmonary
vascular smooth muscle cells (43), and that circulating CD34+-expressing mesenchymal stem
cells contribute to both airway and vascular smooth muscle cell numbers (129, 135), one cannot
assume a similar response between the two distinct smooth muscle cells types to IL-17.
The direct response of the airway smooth muscle cells to IL-17 is somewhat in contrast to
the reports that the involvement of TH17 cells in hypoxic pulmonary hypertension does not
depend on the direct actions of IL-17 on the target cells, specifically pulmonary artery smooth
muscle cells. In these studies, the mediator of hypoxic pulmonary hypertension is IL-21, secreted
from TH17 cells after their polarization with IL-6. TH17 cell mediated production of IL-21 lead to
the upregulation of M2 macrophage signature genes, such as Fizz1, Arf1, and Cxcl12 (57). This
group demonstrated that M2 macrophages are required for the PASMC proliferation associated
with hypoxic pulmonary hypertension. Interestingly, this group also showed that mouse PASMC
do not proliferate in the presence of IL-6, sIL-6R, or both, which is consistent with the reports
from Savale et al. in which they demonstrated that IL-6 treatment of human PASMC markedly
stimulated cell migration, with no effect on cell proliferation (131).

Hypoxia and Lung Inflammation
Hypoxia causes the development of pulmonary artery-specific inflammatory
environment, with a remarkable accumulation of lymphocytes in the lungs that may contribute to
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vascular remodeling in rats (19, 114, 148). Furthermore, chronic cigarette smoke exposure
generates pathogenic T cells that when adoptively transferred to mice lacking a mature adaptive
immune system are capable of driving a COPD-like disease (95). Also, COPD is characterized
by an abnormal persistent inflammatory response (127, 128, 168) with increased circulating
CD4+ T cells (168). Therefore, CD4+ T cells have the potential to play a significant role in the
disease process initiated by hypoxia.
Inflammatory cell infiltration (predominantly CD4+ T cells) is associated with
progressive muscularization of small (<30μm) arterioles, leading to increased pulmonary
vascular resistance. These findings indicate that inflammatory cells, through various mechanisms
have the capability to increase pulmonary vascular resistance in various disease states (19).
These T cells show signs of activation, and are polarized towards a TH1 phenotype. This
results in the recruitment of a variety of inflammatory cells due to the release of proinflammatory cytokines as well as cell-mediated apoptosis through the release of perforin and
granzyme (128)(127)(168)(27).
CH-induced pulmonary hypertension, as opposed to PAH, has generally been thought to
be mediated by less inflammation and more through functional alterations of the vasculature,
such as increased constriction through mechanisms such as enhanced Ca2+ sensitivity of the
contractile apparatus and the muscularization of previously non-muscularized distal vessels. For
the past three decades, two rodent models have been central to the understanding and exploration
of pulmonary hypertension, these are the exposure of animals to CH, and the delivery of the
toxic plant alkaloid monocrotaline (151). CH has led to a greater understanding of the
mechanisms of hypoxia-induced vascular changes and remodeling, the obliterative lesions seen
in human patients with PAH are not seen in the rodents exposed to hypoxia. Monocrotaline is a
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macrocyclic pyrrolizidine alkaloid derived from the seeds of the Crotalaria spectabilis plant.
The alkaloid is activated to the pyrrole metabolite dehydromonocrotaline in the liver via
cytochrome P-450(118, 160). The generally accepted mechanism for monocrotaline’s ability to
cause pulmonary hypertension is due to the toxic effects on pulmonary endothelial cells.
However, the exact toxicological mechanisms by which monocrotaline initiates lung toxicity
remain unclear (48).
In 2011, Cuttica et al. demonstrated that monocrotaline treated mice developed
pulmonary vascular endothelial cell injury, which was orchestrated by a perivascular
inflammatory response. For the first time, the study demonstrated that monocrotaline-induced
pulmonary hypertension was associated with perivascular inflammation, consisting primarily of
CD4+ T cells. This perivascular inflammation resulted in the progressive muscularization of
small (<30µm) arterioles (29). Importantly, and for the first time, this study demonstrated that T
cells, specifically CD4+ T cells contribute to the development pulmonary arterial hypertension.
Their findings highlight the potentially important role of inflammation; specifically CD4+ T cells
in vascular. Interestingly, their findings conflict with previous studies from TarasevicieneStewart and colleagues who demonstrated a protective role for T cells in the development of a
proliferative vasculopathy in athymic nude rats exposed to a vascular endothelial growth factor
receptor 2 inhibitor SU5416 (155). These differences can be largely explained by the gross
differences in the models used, both the animals used and the way in which PH was initiated.

Rationale and Specific Aims
Chronic respiratory diseases are the third leading cause of death in the United States
(101). Chronic respiratory diseases can result in global hypoxia, leading to increased pulmonary
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vascular resistance and PH (99). It is well known that CH causes remodeling of the pulmonary
vascular bed, including hypertrophy of the medial layer of pulmonary arteries(149), and
increased vasoreactivity (138). These responses lead to increased RVSP, RV hypertrophy and
eventual heart failure, or cor pulmonale (139). It has been recognized that autoimmune
phenomena are associated with certain forms of PH (53). Also, previous work has shown that
COPD, a major risk factor for the development of PH, is characterized by an abnormal persistent
inflammatory response (127, 128, 168). While this work has demonstrated that T cells are
increased in the lungs of patients with COPD, the role of inflammation in the development of PH
due to CH is poorly understood (20). IL-6 can be produced by a variety of cells, including
smooth muscle under hypoxic conditions (131). IL-6 is crucial to the development of TH17 cells,
a pro-inflammatory T cell subset involved in a variety of auto-immune phenomena (1). These
cells have the potential to play a key role in the development of CH-induced PH. Therefore, the
objective of this thesis was to evaluate the adaptive immune contribution to PH due to CH. The
focus of these studies was to understand how T cells respond to hypoxia and how this response
results in PH. Our central hypothesis is that an increase in IL-6 in the lung following CH
results in TH17 T cell polarization and TH17-mediated soluble IL-6 receptor production,
which contributes to the development of pulmonary hypertension (Figure 2).
We approached the overall hypothesis through two specific aims.
Specific Aim 1: Determine the contribution of the adaptive immune response to CH-induced PH.
We hypothesize that TH17 cells contribute to CH-induced PH.
Specific Aim 2: Determine the mechanism by which TH17 cells contribute to the development of
pulmonary vascular dysfunction following CH. We hypothesize that increased production of
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IL-6 and the Th17-mediated release of sIL-6R following chronic hypoxia induce pulmonary
artery smooth muscle proliferation and migration, contributing to pulmonary hypertension.
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Figure 2. Central Hypothesis: IL-6: Interleukin-6. sIL6R: soluble interleukin-6 receptor. TH17: T helper 17.
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Rationale: Inflammation is a prominent pathologic feature in pulmonary arterial hypertension as
demonstrated by pulmonary vascular infiltration of inflammatory cells, including T and B
lymphocytes. However, the contribution of the adaptive immune system is not well characterized
in pulmonary hypertension caused by chronic hypoxia. CD4+ T cells are required for initiating and
maintaining inflammation, suggesting these cells could play an important role in the pathogenesis
of hypoxic pulmonary hypertension.
Objectives: To test the hypothesis that CD4+ T cells, specifically the T helper 17 subset, contribute
to chronic hypoxia-induced pulmonary hypertension.
Methods: We compared indices of pulmonary hypertension resulting from chronic hypoxia (3
weeks) in wild-type mice and recombination-activating gene 1 knock-out mice (RAG1-/-, lack
mature T and B cells). Separate sets of mice were adoptively transferred with CD4+, CD8+, or T
helper 17 cells prior to normoxic or chronic hypoxic exposure to evaluate the involvement of
specific T cell subsets.
Results: RAG1-/- mice had diminished right ventricular systolic pressure and arterial remodeling
compared to wild-type mice exposed to chronic hypoxia. Adoptive transfer of CD4+, but not CD8+
T cells, restored the hypertensive phenotype in RAG1-/- mice. Interestingly, RAG1-/- mice
receiving T helper 17 cells displayed evidence of pulmonary hypertension independent of chronic
hypoxia. Supporting our hypothesis, depletion of CD4+ cells or treatment with SR1001, an
inhibitor of T helper 17 cell prevented increased pressure and remodeling responses to chronic
hypoxia.
Conclusions: T helper 17 cells play a key role in the development of chronic hypoxia-induced
pulmonary hypertension.
Keywords: CD4 T cells, inflammation, IL-6, SR1001, RORτ
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Introduction

Chronic hypoxia (CH)-induced pulmonary hypertension (PH) is associated with
respiratory diseases, such as chronic obstructive pulmonary disease (COPD) (36; 47). PH greatly
affects the outcome of COPD (8). Medical regimens for hypoxic PH are currently limited to
supportive therapy (42).
Hypoxia induces a pulmonary artery-specific inflammatory environment, with an
accumulation of lymphocytes in the lungs that may contribute to vascular remodeling in rats (9;
40; 50). COPD is also characterized by an abnormal inflammatory response (44; 60) with increased
circulating CD4+ T cells (60). Therefore, CD4+ T cells have the potential to play a significant role
in the disease process initiated by hypoxia.
CD4+ T cells are responsible for orchestrating immune processes and are critical in
amplifying inflammatory responses by other effector immune cells (21). CD4+ T cells can
differentiate into distinct effector subsets, including T helper 1 (TH1), TH2, TH17 cells and T
regulatory cells (Tregs). TH17 cells are increased in the lungs of patients with COPD (56). It is
unknown whether this response is a consequence of cigarette smoking or hypoxemia. Exposure of
naïve T cells to hypoxic conditions favors differentiation into TH17 cells (14). Furthermore, TH17
cell number increases in lungs of mice exposed to 3 days of CH (23). Although the presence of
TH17 cells has been associated with PH (23; 25), whether TH17 cells can directly induce PH, is
still unknown. Furthermore, studies suggest that Tregs function to limit vascular injury and may
protect against the development of pulmonary arterial hypertension (PAH) and CH-induced PH
(12; 53). Based on these findings, we hypothesized that CD4+ T cells, specifically TH17 cells,
contribute to the development of CH-induced PH. This study identified a critical role for TH17
cells as mediators of pulmonary arterial inflammation and PH following CH exposure.
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Methods
Animals
C57BL/6 RAG1-/- (male and female, 25-28 g), C57BL/6 wild-type (WT) (sex- and agematched), and C57BL/6-Il17atm1Bsgen/J mice (The Jackson Laboratory) were used in these studies.
Protocols were approved by the Institutional Animal Care and Use Committee of the University
of New Mexico Health Sciences Center.
Chronic hypoxia exposure
Mice exposed to CH were housed in a hypobaric chamber (~380 mmHg; 2-21 days).
Control mice were housed at ambient barometric pressure (normoxia, N; ~630 mmHg,
Albuquerque, NM).
Assessment of right ventricular systolic pressure and right ventricular hypertrophy
Peak right ventricular systolic pressure (RVSP) was assessed in isoflurane-anesthetized
mice as previously described (41). RV systolic pressure (RVSP) was measured as an index of
pulmonary arterial pressure in anesthetized mice (2% isoflurane and 98% O2 gas mixture). An
upper transverse laparotomy was performed to expose the diaphragm. A 25-gauge needle,
connected to a pressure transducer (model P23 XL, Spectramed), was inserted into the RV via a
closed-chest trans-diaphragmatic approach, and the output amplified by a Gould Universal
amplifier. All data were recorded, and heart rate was calculated with a computer-based dataacquisition system (AT-CODAS, DATAQ Instruments). After collecting hemodynamic data, the
heart was isolated and the atria and major vessels were removed. The RV was dissected from the
left ventricle (LV) and septum (S). Right ventricular (RV) hypertrophy (Fulton’s index) was
expressed as the percentage ratio of RV to left ventricle plus septum (LV+S) weight and RV to
body weight (BW).
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Vascular morphometry
Pulmonary arterial remodeling (<150 μm outer diameter) was assessed using a
modification of previously published methods (15). After collection of hemodynamic data, the
lungs were perfused via the right ventricle with ~5 ml of modified physiological saline solution
(HEPES-PSS, 134 mM NaCl, 6 mM KCl, 1 mM MgCl, 10 mM HEPES, 2 mM CaCl2, 0.026 mM
EDTA, and 10 mM glucose) containing heparin, 4% albumin (Sigma) and 10−4 M papaverine
(Sigma), at 20 mmHg to maximally dilate and flush the circulation of blood. The heart, lungs and
trachea were removed in block. The right lobes were tied off, removed and preserved in RNA
Later. The left lobe of the blood-cleared lung was fixed in 4% paraformaldehyde (Polyscience,
Warrington, PA) in phosphate-buffered saline (PBS) fixative.
Lung sections (5 μm) were stained with rabbit anti-smooth muscle α-actin (Abcam
Ab5694, Cambridge, MA) (39; 52) antibody or rabbit IgG control (negative) followed by DyLight
549-donkey anti-rabbit (Thermo Fisher Scientific). Sections were examined using a 20 or 40X
objective on a Zeiss Axiovert 200M scope, and images acquired with a Cool Snap EZ camera
using NIS-Elements F 3.0 software. Images were analyzed with Image J (NIH, Bethesda, MD).
Vessels sectioned at oblique angles were excluded from analysis. The analysis was performed in
arteries with less than <150 μm outer diameter. Approximately 10 arteries/animal were analyzed.
% wall thickness = [(external diameter – luminal diameter)/external diameter] x 100. Diameters
were calculated from the measured circumferences
Immunohistochemistry and immunofluorescence
Sections from paraffin-embedded lungs were deparaffinized, rehydrated, washed,
subjected to antigen retrieval for 20 min ≥90°C in a buffer containing 10 mM Tris, pH 9.0 + 1 mM
EDTA in rice cooker and blocked/permeabilized with 1x PBS + 2% normal goat serum + 0.1%
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Triton X-100. Lung sections were incubated with IgG control or rabbit anti-human CD3 primary
antibody (1:400; Dako A052, lot 20024875, stock 0.6 mg/ml) or anti-IL-6 (Ab6672, Abcam) (38)
followed by rat anti-rabbit horseradish peroxidase-conjugated secondary antibody and signal
development with diaminobenzidine (DAB).
Pulmonary arteries were identified based on morphology. The number of CD3+ cells in the
medial and perivascular regions were normalized to outer diameter. Only arteries with <150 µm
outer diameter were analyzed. Samples from each time point were processed and analyzed right
after each set of experiment therefore results from different time points cannot be statistically
compared. Mean gray values of IL-6 staining were quantified in the medial layer of pulmonary
arteries using Image J.
For the detection of Th17 cells, lung sections were incubated with control IgG or rabbit
anti-IL-17 (1:400; AbCam ab79056, lot GR281497-1, stock 1 mg/ml) (26; 54; 59) overnight at
4°C, followed by secondary antibody donkey AlexaFluor 488 anti-rabbit (1:300; Jackson 711-546152, lot 124082) for 1 hr at room temperature and fixed for 15 min with 1x PBS + 1%
formaldehyde (EM-grade). Then, the lung sections were incubated with rabbit anti-CD3 (1:400;
Dako A052, lot 20024875, stock 0.6 mg/ml) overnight at 4°C, followed by secondary antibody
donkey DyLight 549 anti-rabbit (1:800; Jackson 711-505-052, lot 93339) for 1 hr at room
temperature. Sections were counter stained with 0.05 µM AlexaFluor 633 hydrazide to label the
elastic lamina. Images were obtained using a Zeiss AxioPlan 2-Nuance Multi-Spectral Camera and
unmixed to remove tissue auto fluorescence. An unsharp mask filter was applied to the composite
image using Image J.
For the detection of proliferating cells, lung sections were incubated with control IgG or
with rabbit monoclonal anti-Ki67 SP6 clone (1:500, ThermoFisher Scientific RM-9106-S0), and
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detection of apoptotic cells was done using a rabbit polyclonal anti-cleaved caspase 3 (1:250, Cell
Signaling Technology 9661) antibody, overnight at 4°C, followed by secondary antibody donkey
DyLight 549 anti-rabbit. Sections were counter stained with SYTOX green to label nuclei and
AlexaFluor 633 hydrazide to label the elastic lamina. Images were acquired using a Leica TCS
SP5 Spectral Confocal System.
Flow cytometry
A single cell suspension from blood-cleared lungs was prepared by mincing and
subsequent digestion with type IV collagenase, elastase and hyaluronidase (Sigma) in RPMI 1640
for 1 hour at 37°C (34). The digested lungs were pushed through a Falcon 70µm cell strainer and
washed in MACS buffer (PBS, 0.5% BSA, 2mM EDTA). Any remaining red blood cells were
lysed with a hypotonic lysing buffer (NH4Cl 8,024 mg/l, KHCO3 1,001 mg/l, EDTA 3.722 mg/l)
for 30 seconds on ice. Cells were incubated for 4 hr with phorbol 12-myristate 13-aceate (PMA;
50 ng/ml), ionomycin (1 μg/ml), and a protein-transport inhibitor (GolgiStop with monensin; BD
Biosciences) before immunostaining to enhance the sensitivity of IL-17A detection. FC receptors
were blocked with anti-CD32/CD16 antibody (rat IgG2b anti-mouse CD16/CD32 monoclonal,
101330, BD Biosciences San Jose, CA) for 10 minutes at room temperature. Cells were washed
and stained with PerCP/Cy5.5 anti-mouse CD4 (clone GK1.5, 100432, BioLegend, San Diego,
CA), APC/Cy7 anti-mouse CD3 (clone 145-2C11, 100330, BioLegend, San Diego, CA), and PE
anti-mouse IL-17A (clone TC11-18H10.1, 506910, BioLegend, San Diego, CA) or PE antimouse/rat/human FoxP3 (clone 150D, 32008, BioLegend, San Diego, CA) for 1 hour at 4°C in the
dark. Macrophages were detected by staining the lung digest with APC anti-mouse CD45 (103112,
BioLegend, San Diego, CA), PE/Cy7 anti-mouse F4/80 (123114, BioLegend, San Diego, CA) and

57

Alexa Fluor® 488 anti-mouse CD11c (117311, BioLegend, San Diego, CA) for 1 hour at 4°C in
the dark.
T cell polarization
Lymphocyte populations were isolated from lymph nodes by negative selection according
to Miltenyi Biotec Magnetic Cell Sorting T Cell Isolation Kits. Cell enrichment was assessed by
flow cytometry. Since TH17 cells lack unique surface markers, CD4+ T cells were purified as
described above from C57BL/6-Il17atm1Bsgen/J mice which express enhanced green fluorescence
protein (EGFP) in cells expressing IL-17A. CD4+ T cells were polarized to TH17 cells following a
published protocol (57) by placing them in 6 well culture dishes pre-coated with anti-mouse CD3ε,
clone 145-2c11 (2 µg/ml). The cells were cultured for 3 days in the presence of anti-mouse CD28
(5 µg/ml), IL-6 (50 ng/ml), TGF-ß1 (1 ng/ml), anti-mouse IL-4 (10 µg/ml), anti-mouse IFN-γ (10
µg/ml) and mouse IL-23 (5 ng/ml, BioLegend, San Diego, CA). On day 3, cells were separated
using automatic fluorescence activated cell sorting based on EGFP fluorescence intensity.
T cell subsets adoptive transfer
Approximately 250,000 complete (naïve and memory) CD4+ or CD8+ T cells were
transferred to RAG1 KO mice via retro-orbital injection (13). Approximately 10,000 TH17 cells
were adoptively transferred to RAG1 KO mice using the retro-orbital approach. All RAG1-/- mice
received the adoptive transfer of T cell subsets or saline 2 weeks before they were exposed to
normoxia or CH for 3 weeks. Mice were monitored for 2 weeks following adoptive transfer, and
weighed periodically to ensure health prior to exposure to CH or normoxia. Following
hemodynamic measurements at the conclusion of the experiments, spleens were removed and
splenocytes were processed for flow cytometry to verify successful engraftment of adoptively
transferred lymphocytes.
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CD4+ T cell depletion
Rat anti-mouse CD4 (clone GK1.5) antibody or control purified IgG2b isotype control
(Biolegend, San Diego, CA) was injected into mice (i.p.; 4 µg/g body wt.) 7 days prior to CH
exposure and weekly for 3 additional weeks (22). Following experiments, CD4+ T cell depletion
was assessed using flow cytometry on single cell suspensions of splenocytes.
Drug treatment
SR1001 (N-(5-(N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) phenyl) sulfamoyl)4-methylthiazol-2-yl) acetamide) a synthetic inverse agonist specific for RORα and RORγτ (Kis =
172 and 111 nM, respectively) was synthesized in house (49). SR1001 (5; 49) was dissolved in
propylene glycol (vehicle) and injected s.c. for 5 days during normoxia or CH exposure (25
mg/kg/day). For the prevention study, vehicle or SR1001 was delivered by osmotic pump for 21
days during normoxia or CH exposure. For the reversal study, mice were exposed to CH for 21
days, then osmotic pump containing vehicle or SR1001 were implanted and mice were treated for
14 days during CH exposure. Both RORα and RORγ have roles outside of the immune system and
are critical regulators of hepatic metabolism. It has been reported that SR1001 administration to
C57BL/6 mice suppressed the expression of hepatic ROR target genes Cyp7b1, Nr1d1 (also called
Rev-erbα) and Serpine1 (also called PAI-1), indicating that this class of compound may have
metabolic effects; however, no obvious toxicity was observed in animals treated with SR1001(49).
We also did not observe any obvious toxicity in mice treated with SR1001.
Pulmonary artery smooth muscle cell migration and confluency assay
Primary pulmonary arterial smooth muscle cell (PASMC) cultures were established and
cells authenticated as previously described (27; 37). PASMC were plated on gelatin-coated dishes
and cultured in Smooth Muscle Cell Medium (Cell Biologics) containing 10% fetal bovine serum
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and antibiotic-antimycotic solution in a humidified atmosphere of 5% CO2-95% air at 37°C. To
measure cell migration or cell numbers, an IncuCyte (Essen Bioscience) live-cell imaging system
was used. Before experiments, PASMC were cultured for at least 48 hr in Serum-free Smooth
Muscle Cell Medium containing insulin, EGF, hydrocortisone, L-glutamine, antibioticantimycotic solution (M2268SF Cell Biologics). Migration was determined by using a
WoundMaker (Essen Bioscience) to produce homogenous, 700-800 µm wide scratch wounds on
a confluent monolayer of PASMC. Cell count was assessed by determining the confluency of the
culture over time, divided by the initial confluency. Images were captured every hour for a total of
60 hour. Cells were incubated with or without 100 ng/ml of E. coli-derived recombinant mouse
IL-17A (R&D Systems).
RT-PCR
Total lung RNA was extracted using Direct-zol (Zymo Research) and reverse transcribed
to cDNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies). The
Roche Universal Probe Library System was used for real- time detection of IL-6 (5’
gctaccaaactggatataatcagga,

3’

ccaggtagctatggtactccagaa,

probe

6),

IL-21

(5’

ccaggtagctatggtactccagaa, 3’ ccaggtagctatggtactccagaa, probe 100), Fizz1 (5’ ccctccactgtaacgaag
actc, 3’ cacacccagtagcagtcatcc, probe 51), NOS2 (5’ ctccatgactcccagcaca, 3’actctcttgcggaccatctc,
probe 101) and ACTB as a reference gene (5’ ctaaggccaaccgtgaaaag, 3’ accagaggcatacagggaca,
probe 64). The normalized gene expression method (2-ΔΔCT) was used for relative quantification
of gene expression using pooled samples as the calibrator (46).
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Statistics
Results were expressed as the mean ± standard error. Statistical significance was tested at
the 95% (p<0.05) confidence level using an unpaired t-test or two way ANOVA followed by
Student-Newman-Keuls post-test.

Results
CD4+ T cells contribute to CH-induced pulmonary hypertension
To assess the contribution of T cells to CH-induced PH, we used recombination-activating
gene 1 knockout (RAG1-/-) mice, which lack mature T and B cells (35). RAG1-/- mice were exposed
to CH or normoxia for 21 days. WT mice exhibited a significant increase in RVSP following CH
(Figure 1A, B). However, this response to CH was largely attenuated in RAG1-/- mice that did not
receive adoptive transfer or saline injection (No AT). Furthermore, adoptive transfer of CD4+ T
cells but not CD8+ T cells was sufficient to restore the increased RVSP following CH (Figure 1B).
Similar results were observed for Fulton’s index (Figure 1C) and RV/body weight (Table 1).
Adoptive transfer did not affect hematocrit, body weight, heart rate, or LV+S/body weight (Table
1). CH significantly increased % arterial wall thickness in WT mice, which was not present in
RAG1-/- mice (Figures 1D, E). Adoptive transfer of CD4+ but not CD8+ T cells into RAG1-/- mice
and subsequent exposure to CH demonstrated an increase in medial thickness similar to that
observed in WT mice.
Adoptive transfer of either cell type did not affect any of the assessed parameters in
normoxic mice (Figure 1 and Table 1), indicating that the observed differences between groups
were not due to the adoptive transfer per se, but rather due to CD4+ T cell restoration. As previously
reported, responses to CH were not different between males and females (6).
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Figure 1. CD4+ T cells contribute to CH-induced PH (A) Representative right ventricular systolic pressure (RVSP)
traces from isoflurane-anesthetized wild-type (WT) and RAG1-/- mice without adoptive transfer (AT) or AT of
enriched CD4+ or CD8+ T cells exposed to 21 days of CH or normoxia, as indicated. (B) Summary of peak RVSP
data. (C) %RV/LV+S weight. Values are means ± SEM. n=animals. *p<0.05 vs. normoxia, #p<0.05 vs. CH WT,
&p<0.05 vs. CH RAG1-/- No AT, analyzed by 2-way ANOVA followed by multiple comparisons Student-NewmanKeuls test. (D) Representative images of α-smooth muscle actin-labeled pulmonary artery sections with external
diameters <150 µm from normoxic and CH (21 days) WT and RAG1 -/- mice receiving either no adoptive transfer or
adoptive transfer with enriched CD4+ or CD8+ T cells, scale bar = 100μm . (E) % wall thickness of pulmonary arteries
from the groups described in A. Values are means ± SEM; n= animals, value is the mean of a minimum of 10 arteries
per animal; *p<0.05 vs. normoxia, #p<0.05 vs. WT CH, &p<0.05 vs. No AT CH, analyzed by 2-way ANOVA
followed by multiple comparisons Student-Newman-Keuls test.
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Table 1. Biometrics of WT and RAG1-/- mice exposed to normoxia or CH, with or without the
adoptive transfer of CD4+ or CD8+ T cells.
HR

Hto

BW

LV+S/BW

RV/BW

(bpm)

(%)

(g)

(mg/g)

(mg/g)

N

N

Treatment Exposure

WT

Normoxia

388±13 41±2

WT

CH

No AT

22.7±1.0 3.04±0.10

(mice) (Females)

0.83± 0.08

7

3

407±40 60±2* 21.8±0.9 3.65±0.10*

1.50±0.06*

7

3

Normoxia

377±23 42±2

0.92±0.04

6

3

No AT

CH

413±10 51±3* 24.6±1.3 3.46±0.10

1.20±0.10*#

6

3

CD4 AT

Normoxia

424±20 40±1

0.86±0.04

6

3

CD4 AT

CH

383±20 58±1* 22.9±1.6 3.44±0.24

1.33±0.04*

6

3

CD8 AT

Normoxia

408±30 40±1

0.92±0.06

7

3

CD8 AT

CH

428±16 53±2* 23.3±2.1 3.43±0.20

1.10±0.05#

7

3

28.1±1.3 3.39±0.08

24.9±1.3 2.88±0.10

26.7±1.8 3.27±0.11

Values are means ± SE. WT = wild-type, AT= adoptive transfer, HR = heart rate, Hto = hematocrit, BW = body
weight, LV+S = left ventricle + septum, RV = right ventricle. CH = chronic hypoxia; *p < 0.05 vs. normoxia, #p<0.05
vs. WT.
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We further tested the contribution of CD4+ T cells to CH-induced PH by depleting CD4+
cells using a CD4 neutralizing antibody. The efficacy of CD4+ cell depletion is demonstrated by a
reduction of CD4+ T cells from 60% to 1% of total CD3+ T cells in the spleen (Figure 2A). As
expected, WT mice receiving control antibody and exposed to CH for 21 days demonstrated an
increase in RVSP, hematocrit, RV hypertrophy, and pulmonary arterial remodeling (Figures 2B,
C, D, E). CD4 depletion prevented the CH-induced increase in RVSP and arterial wall thickness
(Figure 2B, D). While there was a blunted RV remodeling response to CH in RAG1-/- mice (Figure
1C), this effect was statistically significant in CD4+ cell-depleted mice (Figure 2C). Body weight,
heart rate, RV/body weight, LV+S/body weight (Table 2) and hematocrit (Figure 2E) were also
unaltered by CD4 depletion. These findings demonstrate that CD4+ T cells contribute to CHinduced PH.
CH increases lung IL-6 levels
The development of TH17 cells relies primarily on the presence of elevated levels of IL-6
(28). Therefore we sought to examine lung IL-6 expression in normoxic and CH mice. Exposure
of WT mice to 5 days of CH, a time previously reported to enhance IL-6 production (45), caused
a significant increase in lung IL-6 mRNA levels (Figure 3A). Furthermore, IL-6 immunostaining
was greater in the medial layer of pulmonary arteries of mice exposed to 5 days of CH compared
to normoxic controls (Figure 3B, C).
TH17 cells but not Tregs are increased in the lung following CH
Studies show increased numbers of circulating TH17 cells in patients with PAH (25) and
COPD (56), and in lungs of CH-exposed mice (23). The proportion of Tregs among CD4+ T cells
is significantly higher in PAH patients than in controls (43) and Tregs suppress adaptive immune
responses (1). However, it is currently unknown
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Figure 2. CD4+ cell depletion attenuates the development of CH-induced PH. Anti-CD4 or control antibody (2
mg/kg) given once per week, starting 1 week before CH (21 days). (A) Representative flow cytometry plots of
splenocytes labeled for CD3 (gated), CD4, and CD8. (B) Peak RVSP. (C) Fulton’s index. (D) % wall thickness. (E)
Hematocrit. Values are means ± SEM. *p<0.05 vs. normoxia, #p<0.05 vs. CH control, n= animals and in (D) value is
the mean of a minimum of 10 arteries per animal, 2-way ANOVA followed by multiple comparisons StudentNewman-Keuls test.
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Table 2. Biometrics of WT mice treated with either control antibody or anti-CD4 antibody.
HR

Hto

BW

LV+S/BW

RV/BW

N

(bpm)

(%)

(g)

(mg/g)

(mg/g)

(mice)

Treatment Exposure

Control

Normoxia

407±24

39.7±0.7

28.1±1.0

2.97±0.28

0.78± 0.01

3

Control

CH

365±47

59.0±1.4* 27.0±0.6

3.72±0.19

1.23± 0.05*

6

Anti-CD4

Normoxia

421±27

40.8±0.4

2.90±0.26

0.77±0.06

3

Anti-CD4

CH

399±10

60.2±1.9* 26.3±0.7* 3.73±0.27

1.23± 0.04*

6

31.1±2.4

Values are means ± SE. WT = wild-type, AT = adoptive transfer, HR = heart rate, Hto = hematocrit, BW = body
weight, LV+S = left ventricle + septum, RV = right ventricle. CH = chronic hypoxia; *p < 0.05 vs. normoxia. Only
male mice were used.
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whether CH alters lung TH17/Treg balance. Therefore, the percent of CD4+ FoxP3+ cells relative
to total CD3+ T cells was determined concurrently with CD4+ IL-17A+ in lung digests of mice
exposed to 5 days of CH or normoxia using flow cytometry. CH resulted in a 4-fold increase in
lung TH17 cells (Figure 4A, B). No significant difference in the percent of CD4- IL-17A+ cells
(data not shown) and CD4+ FoxP3+ (Figure 4A, B) relative to total CD3+ T cells was detected in
lungs between normoxia- and CH-exposed mice.
In addition, total lung CD3+ and CD3+/CD4+ T cells were similar between normoxic and
CH mice (Figure 4C, D).
TH17 cell development depends on signaling from the nuclear receptors RORα and RORγτ
(58). SR1001 inhibits these receptors and TH17 cell development both in vitro and in vivo (49). To
confirm this effect of SR1001 in our preparation, mice were treated with vehicle or SR1001 and
exposed to CH for 5 days or left in normoxia, and lung TH17 and Tregs were measured by flow
cytometry. SR1001 significantly attenuated CH-induced increases in lung TH17 cells with no effect
in normoxic mice (Figure 4A, B). In contrast, SR1001 significantly increased Tregs in both
normoxic and CH-exposed mice (Figure 4A, B).
To determine whether the increase in lung TH17 cells is localized to the perivascular region,
mice were treated with SR1001 and exposed to CH for 2, 5 or 21 days. T cells were examined in
lung sections by immunohistochemical detection of the pan-T cell marker CD3. CH increased the
incidence of CD3+ T cells in the pulmonary arterial perivascular region of vehicle-treated mice
(Figure 5A, B). SR1001 prevented this response to CH at all three time points (Figure 5A, B). The
majority of perivascular CD3+ cells were found to be IL-17A+ in arteries from CH mice (Figure
5C). The increase in perivascular T cells following CH was not due to an increase in total lung T
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Figure 3. CH increases lung IL-6 levels. (A) Lungs from mice expose to either normoxia or 5 days of CH (CH 5d)
were homogenized and IL-6 mRNA levels determined by real time PCR, using beta actin as an endogenous control.
(B) Representative images of immunohistochemical detection of IL-6 in lung sections. (C) Summary analysis data of
the mean gray value of the medial layer of anti-IL-6-stained pulmonary artery sections with external diameters of 3080 μm. Values are means ± SEM, *p<0.05 vs. normoxia. n=3 mice/group, 5-12 arteries per mouse, analyzed by
unpaired t-test.
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Table 3. Biometrics of RAG1-/- mice exposed to normoxia or CH, with or without the adoptive
transfer of TH17 cells.
HR

Hto

BW

LV+S/BW

RV/BW

N

N

(bpm)

(%)

(g)

(mg/g)

(mg/g)

28.1±1.3

3.39±0.08

0.92±0.04

6

3

1.20±0.10*

6

3

0.80±0.04&

6

3

1.19±0.05*

6

3

Treatment Exposure

No AT

Normoxia

377±23 42±2

No AT

CH

413±10 51±3* 24.6±1.3* 3.46±0.10
26.0±0.3

3.02±0.06&

TH17 AT Normoxia

423±12 40±2

TH17 AT CH

415±19 53±1* 22.1±1.2* 3.14±0.09

(mice) (Females)

Values are means ± SE. WT = wild-type, AT = adoptive transfer, HR = heart rate, Hto =
hematocrit, BW = body weight, LV+S = left ventricle + septum, RV = right ventricle. CH = chronic
hypoxia; *p < 0.05 vs. normoxia, &p<0.05 vs. No AT normoxia.
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cells (Figure 4C). Furthermore, SR1001 did not affect T cell density in the in lung parenchyma
(Figure 5D).
TH17 cells contribute to CH-induced PH
SR1001 administration attenuated CH-induced increases in RVSP, RV hypertrophy,
pulmonary arterial remodeling, and increases in Ki67+ (proliferation marker) cells in the wall of
small pulmonary arteries without affecting the polycythemic response (Figure 6). No apoptotic
cells were detected in pulmonary arteries from any of the groups (Figure 6F).
To further confirm a role for TH17 cells in CH-induced PH, in vitro-polarized TH17 cells
were administered to RAG1-/- mice exposed to CH or normoxia. Mice receiving TH17 cells
developed an increase in RVSP along with pulmonary arterial remodeling, independent of
normoxic or CH exposure (Figure 7A, B). Interestingly, RV remodeling did not develop in
normoxic mice receiving adoptive transfer (Figure 7C) despite evidence of PH. Rather, both
RV/body weight and LV+S/body weight were significantly lower in normoxic RAG1-/- mice that
received adoptive transfer of TH17 cells compared to those not receiving adoptive transfer (Table
3). This effect was not due to a decrease in body weight (Table 3). The polycythemic response to
CH was not affected by adoptive transfer of TH17 cells (Figure 7D). Successful adoptive transfer
was demonstrated by CD3+ T cell labeling in lung sections from adoptively transferred mice, but
not in sham (saline)-treated mice (Figure 7E). CD4+ EGFP+ cells were also found in the spleen by
flow cytometry (Figure 7F).
TH17 cell inhibition lowers RVSP in established PH.
We sought to understand whether CH-induced PH can be reversed once already established
by inhibiting TH17 cell development. Consistent with this possibility, SR1001 significantly
lowered RVSP (Figure 8A). A trend for decreased RV hypertrophy (p<0.0583) and pulmonary
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Figure 4. CH leads to an increase in lung TH17 cells without affecting Tregs. Lungs were removed from vehicleand SR1001 (25 mg/kg/day s.c.)-treated mice after 5 days of normoxic or CH (CH 5d) exposure. Single cell
suspensions from the lungs were labeled with anti-CD3, anti-CD4, and anti-IL-17A or FoxP3. (A) Representative
scatter plots. Cells were gated based on forward and side scatter and CD3 CD4. (B) Summary of the percent of CD4+
IL-17A+ or CD4+ FoxP3+ cells relative to total CD3+ cells normalized to the average of vehicle-treated normoxic
group of each set of experiments. (C) Representative scatter plots of CD3+, CD4+ T helper cells from lungs from mice
exposed to normoxia or 5 days of CH. (D) Summary of the percent of CD3+ T cells relative to total cells and CD3+,
CD4+ T helper cells relative to total CD3+ cells. Values are means ± SEM, n= animals, *p<0.05 vs. normoxia vehicle,
#p<0.05 vs. CH vehicle, analyzed by 2-way ANOVA followed by multiple comparisons Student-Newman-Keuls test.
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Figure 5. Inhibition of TH17 cell development attenuates CH-induced increases in perivascular T cells. SR1001 was
delivered daily by s.c. injection (25 mg/kg/day) for the duration of normoxic or CH exposure. (A) Representative
images from normoxic and CH (5 days) mice, treated with or without SR1001 in which perivascular T cells (CD3 +
cells) were quantified. Arrows depict CD3+ cells. Scale bar=100 µm. (B) Summary of the number of perivascular
CD3+ cells from mice exposed to 2, 5 or 21 days of normoxia or CH, treated with or without SR1001. The perivascular
region was defined as external to vessel media, and internal to vessel adventitia. (C) Representative images of lung
sections from vehicle-treated mice exposed to 21 days of CH co-labeled with anti-IL17A (green) and anti-CD3 (red).
Elastic lamina is shown in blue. Arrows depict double-positive cells. Scale bar=50 µm. (D) Summary of the number
of CD3+ cells in the lung parenchyma of mice exposed 5 days of normoxia or CH, treated with or without SR1001.
Values are means ± SEM, *p<0.05 vs. normoxia vehicle, #p<0.05 vs. Vehicle CH. n= animals, value is the mean of
5-15 arteries (<150 µm outer diameter) per mouse, analyzed by 2-way ANOVA followed by multiple comparisons
Student-Newman-Keuls test.
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arterial remodeling (p<0.20) was also observed (Figures 8B, C). SR1001 decreased the number of
perivascular T cells (Figure 8D).
IL-17A increases mouse PASMC migration.
Controversy exists as to whether TH17 cells can have a direct effect on tissue through the
release of TH17-associated cytokines (23; 30) or indirectly by recruiting neutrophils and/or
macrophages (31). To determine whether macrophages are implicated in the pathogenesis of PH
in our experimental conditions, total macrophage numbers were determined by flow cytometry in
lungs of vehicle- and SR1001-treated mice exposed to normoxia or 5 days of CH. No significant
difference in the percent of F4/80+ CD11b+ cells relative to total CD45+ cells was detected between
groups (Figure 9A, B). IL-21 transcript levels were additionally measured in the lungs of mice
exposed to normoxia or 5 days of CH together with mRNA levels of the M2 marker, Fizz1, and
the M1 marker, NOS2. No significant differences in IL-21, Fizz1 or NOS2 mRNA levels were
found between groups (Figure 10). Furthermore, IL-17A increased mouse PASMC migration as
assessed using a scratch-wound healing assay (Figure 11A) but had no effect on cell culture
confluency (Figure 11B).
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Figure 6. Inhibition of TH17 cell development attenuates CH-induced PH. SR1001 was delivered s.c. (25
mg/kg/day) via an implantable osmotic pump. (A) RVSP following 21 days of normoxia or CH. (B) Fulton’s index.
(C) Pulmonary arterial wall thickness measured in small pulmonary arteries (<150 µm) labeled for α-smooth muscle
actin. (D) Hematocrit. (E) Number of Ki67+ cells/small pulmonary artery outer diameter. Ki67 is a marker of cell
proliferation. Ki67+ cells were detected by immunofluorescence microscopy in the arterial wall (shown in red). The
elastic lamina in the arterial wall is shown in blue. Nuclei are shown in green. CH 5d = 5 days of CH. (F)
Representative images of lung sections labeled with anti- cleaved caspase 3 which is an apoptosis marker. Scale bar
= 40 µm. Arrows depict positive cells expressing activated caspase 3 in lung parenchyma. Values are means ± SEM;
n= animals and in (C) and (D) value is the mean of a minimum of 10 arteries per animal, *p<0.05 vs. normoxia vehicle
#p<0.05 vs. normoxic SR1001, analyzed by 2-way ANOVA followed by multiple comparisons Student-NewmanKeuls test.
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Figure 7. The adoptive transfer of TH17 cells causes spontaneous PH in RAG1-/- mice. CD4+ T cells were purified
from IL-17A EGFP mice and cultured under TH17 polarizing conditions. TH17 cells were purified by fluorescence
activated cell sorting (FACS) and injected into RAG1 -/- mice. After 14 days, mice remained in normoxia or were
exposed to CH for 21 days and compared to mice that did not receive T H17 cells. (A) RVSP. (B) % Wall thickness.
(C) Fulton’s index. (D) Hematocrit. (E) Representative images of lung sections immuno-stained for CD3 from mice
receiving adoptive transfer or a RAG1-/- mouse which received no adoptive transfer. Scale bars =100 µm. (F) Flow
cytometric analysis of TH17 cells from the spleen of mice that receive an adoptive transfer. Values are means ± SEM;
n= animals, *p<0.05 vs. normoxia, #p<0.05 vs. normoxia No AT, &p<0.05 vs. CH No AT. Analyzed by 2-way
ANOVA followed by multiple comparisons Student-Newman-Keuls test.
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Figure 8. Inhibition of TH17 cell polarization reverses CH-induced PH. Wild-type mice were exposed to CH for 21
days followed by administration of SR1001 (25mg/kg/day s.c.) or vehicle for an additional 14 days in CH. (A) RVSP.
(B) Fulton’s index. (C) % wall thickness. (D) Number of CD3+ cells/vessel diameter (µm). Values are means ± SEM;
n= animals and in (C) and (D) value is the mean of a minimum of 10 arteries per animal, *p<0.05 vs. vehicle, analyzed
by unpaired t-test.
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Figure 9. Total lung macrophage numbers are not affected by CH exposure. Lungs were removed from mice following
5 days of CH exposure. Single cell suspensions from the lungs were incubated with anti-CD45, anti-F4/80 and antiCD11b to label macrophages. (A) Representative scatter plots. Cells were gated based on forward and side scatter and
CD45. (B) Summary of the percent of F4/80+ CD11c+ cells relative to total CD45+ cells normalized to the average of
vehicle-treated normoxic group of each set of experiments. Values are means ± SEM, n= animals, analyzed by 2-way
ANOVA followed by multiple comparisons Student-Newman-Keuls test.
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Figure 10. CH does not affect lung IL-21, Fizz1 and NOS2 mRNA levels. IL-21, Fizz1 (macrophage type 2 marker)
and NOS2 (macrophage type 1 marker) transcripts were measured by real-time PCR in lungs from WT mice exposed
to normoxia or 5 days of CH. Values are means ± SEM, n= animals, analyzed by unpaired t-test.
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Figure 11. IL-17A stimulates migration but does not affect mouse pulmonary arterial smooth muscle cells number
in culture. (A) Percent wound density in the presence or absence of IL-17A (100 ng/ml). (B) Confluency density
normalized to time 0 in the presence or absence of IL-17A (100 ng/ml) in serum starved cells. Growth media was used
a positive control. *p<0.05, cells from n=4 mice, 2-way repeated measures ANOVA followed by multiple comparisons
Student-Newman-Keuls test.
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Discussion
In both humans and rodents, alveolar hypoxia results in an inflammatory phenotype in the
lung (9; 19; 20; 24; 33; 50). Inflammation occurs before morphologic changes in the vasculature,
suggesting that lung hypoxia may lead to damaging inflammatory effects (20). Release of
cytokines and chemokines from inflamed tissues may contribute to differentiation of naïve T cells
into mature effector T cells and their migration to the site of inflammation. However, the
contribution of T helper subsets to the pathogenesis of hypoxic PH is not clear, and the mechanism
and specific inflammatory cell types involved are not well defined. Our study shows that CD4+ T
cells, specifically TH17 cells, contribute to CH-induced PH, and their presence in the perivascular
space likely contributes to this disease.
Cuttica et. al (13) reported that RAG1-/- mice are protected from monocrotaline-induced
PAH and that CD4+ T cells are the primary effector cells. However, the role for CD4+ T cells in
PH due to CH has not been directly assessed. For the first time, our study demonstrates that CD4+
T cells are both necessary and sufficient for a robust pulmonary hypertensive response to CH. In
addition, our study suggests that CD8+ T cells might not contribute to CH-induced PH because
immune reconstitution of RAG1-/- mice with CD8+ T cells did not affect the already attenuated
response of these mice to CH. Furthermore, our data suggests that B cells are not major
contributors to the pathogenesis of PH since CD4+ T cells reconstitution fully restored the
pulmonary hypertensive response to CH in RAG1-/- mice and CD4+ T cells depletion attenuated it.
Further supporting a minimal role for B cells, in an initial pilot study, adoptive transfer of
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splenocytes from a T cell receptor knockout mouse (lacks all mature T cells but has B-cells) failed
to restore the PH response in RAG1-/- mice (data not shown).
Inflammation in rat pulmonary arteries after CH exposure has been characterized by
increased numbers of monocytes and dendritic cells, with few T cells and no B cells (9).
Conversely, in monocrotaline-treated mice, perivascular infiltration largely involves CD4+ T cells,
along with fewer macrophages and B cells (13). However, the subset of CD4+ T cells involved in
the pathogenesis of PH or PAH is not clear.
TH17 cells are important mediators of tissue damage in immune-mediated inflammatory
diseases such as asthma, inflammatory bowel disease (55), and cardiovascular diseases (11; 18),
including systemic hypertension (32). TH17 cells act by attracting neutrophils, stimulating the
release of matrix metalloproteinases, as well as increasing the release of factors from resident cells
(31). The development of TH17 cells relies primarily on the presence of elevated levels of IL-6
(28; 29). Increased numbers of circulating TH17 cells have been reported in COPD (56) and PAH
patients (25). Hasimoto-Kataoka et. al (23) have recently shown an effect of CH (3 days) to
increase lung TH17 cell numbers in mice, which was prevented by administration of an anti-IL-6
receptor antibody. However, these previous studies have neither addressed where these cells
accumulate in the lungs nor their contribution to PH. Our results demonstrate that CH increases
the proportion of TH17 cells without affecting the proportion of Tregs or total T cell numbers in
the lungs and that increased TH17 cells are localized in the perivascular region of small pulmonary
arteries. The increase in TH17 cells was associated with increased lung IL-6 mRNA and peptide
levels in the medial layer of pulmonary arteries. These results showing increased lung IL-6
expression in response to CH are consistent with previous report demonstrating that IL-6 plays a
critical role in the development of PH (23; 45). Although IL-6 inhibits TGF-β-induced Treg
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differentiation (28), our results suggest that in CH, the balance of TH17/Treg is altered in the lung
due to an increase in TH17 cells but not due to changes in Tregs. However, these findings do not
preclude the possibility that Treg numbers are altered at different exposure times. In addition, the
decreased proportion of Tregs in the lungs could have affected the pathogenesis of PH since it has
been shown that adoptive transfer of Tregs into WT mice prevents CH-induced PH (12).
Our study demonstrates a novel effect of a TH17 inhibitor, SR1001, to attenuate the
development of CH-induced PH. Furthermore, mice that received adoptive transfer of TH17 cells
under normoxic conditions developed spontaneous increases in RVSP and pulmonary arterial
remodeling. Thus, our data strongly support a pathogenic role of TH17 cells in the development of
PH. Interestingly, we found that lungs of mice that received the adoptive transfer of T H17 cells
under normoxic conditions displayed a remarkable increase in the number of CD3+ T cells in both
the parenchymal and perivascular region. These data suggest that polarizing naïve CD4+ T cells to
TH17 cells ex vivo mimics conditions occurring in the lung in response to CH.
It is possible that RORτ+ innate lymphoid cells (2) contribute to CH-induced PH.
However, this possibility is unlikely because: 1) no significant increase in CD3+ CD4- IL-17A+
cells was detected by flow cytometry in the lungs of mice exposed to CH compared to controls, 2)
CD4+ T cell-replete RAG1-/- mice developed PH in response to CH, 3) normoxic mice that received
TH17 cells displayed evidence of PH, and 4) most CD3+ T cells present in the perivascular region
were IL-17A+.
A dissociation between RVSP and RV remodeling was observed in CD4+ cell-deplete
(Figure 3) and TH17 cell-replete mice (Figure 8). While it has been widely believed that sustained
pressure overload is sufficient to result in adaptive hypertrophy of the heart, this and other studies
(3; 16; 41; 51) suggest hypoxia itself is a major contributor to RV remodeling through mechanisms
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that are partially independent of pressure overload. The mechanism that underlies the dissociation
between RVSP and RV remodeling is currently unknown.
The heart weight of mice that received adoptive transfer of TH17 cells under normoxic
conditions was lower than control mice. These mice appeared healthy, in that they did not show
indications of colitis, and their weight remained relatively stable. Therefore, the decrease in heart
weight cannot be explained by a general state of stress induced by a systemic inflammatory
reaction. The reason of the decrease in heart weight is currently unknown and requires further
investigation.
To follow up on the immunologic timing of events, we sought to understand whether PH
due to CH might be reversed by inhibition of TH17 cell polarization. We demonstrated that
established PH markers, such as increased RVSP, can be reduced by treating animals with SR1001.
We observed a strong tendency for a reduction in RV remodeling and a significant decrease in
perivascular T cell infiltration. The reversal of fixed components (remodeling) of PH might require
longer treatment. It has been previously demonstrated that SR1001 prevents the polarization of
naïve CD4+ T cells to TH17 cells and significantly delays the onset of TH17 cell-mediated
experimental autoimmune encephalomyelitis in mice and reduces disease severity (49). This is
similar to our results in which SR1001 was more effective if given earlier in disease progression,
rather than after disease is well established. Our data indicate that significant perivascular T cell
infiltration persists after 21 days of CH. Therefore, it is likely that there is an initial contribution
of CH to the polarization of naïve CD4+ T cells, which establishes disease, but long standing, lower
levels of chronic inflammation may help sustain CH-induced PH.
Contrary to Solt et. al’s report showing that SR1001 has no effect on Treg development in
vitro (49), but consistent with in vivo studies (7; 48), here we show that SR1001 increases lung
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Tregs suggesting an additional mechanism by which SR1001 could have prevented and reversed
CH-induced PH (12). However, several lines of evidence support TH17 cells as the major effector
inflammatory cells following CH, including: 1) the majority of perivascular T cells were IL-17A+;
2) SR1001 did not affect the number of perivascular CD3+ T cells in normoxic mice while
preventing CH-induced perivascular inflammation; and 3) CH did not increase lung Tregs. Further
studies exploring the mechanism by which ROR inhibitors alter TH17/Treg balance are warranted.
TH17 cells are characterized by the predominant production of IL-17A (4). We found that
IL-17A enhanced PASMC migration but did not affect cell number or confluency. These results
are consistent with a report showing that IL-17A promotes migration of airway smooth muscle
cells (10) but contrary to a report showing that it enhances fibroblast proliferation (17). Therefore,
our results suggest that IL-17A produced by TH17 cells plays an important role in the pathogenesis
of CH-induced PH. It has been reported that TH17 cells promote M2 macrophage polarization
through the release of IL-21 (23), however, we did not find a significant change in lung
macrophage infiltration, IL-21 mRNA, or expression of M2 or M1 markers in response to CH. A
few differences in experimental design could explain the discrepancy between studies. For
example, the earlier study used normobaric hypoxia with no CO2 supplementation while we used
hypobaric hypoxia, they determined these markers in bronchoalveolar lavage while we used whole
lung, and although we both used C57B6 mice, the mice were from different sources. Regardless,
further studies are warranted to establish the mechanism of TH17 cell-mediated PH pathogenesis.
In summary, this study directly demonstrates a causal link between CD4+ T cells and PH
under hypoxic conditions, specifically pointing to TH17 cells. It also demonstrates that CH
increases perivascular T cell localization, a response that is prevented by an inhibitor of RORτ,
the signature nuclear receptor for TH17 cells. Furthermore, our findings suggest that inhibition of
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TH17 cell development may provide a novel therapeutic approach to treat pulmonary hypertensive
patients.
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Abstract
Interleukin 6 (IL-6) is a pleiotropic cytokine with a wide range of biologic activities in immune
regulation, hematopoiesis, inflammation, and oncogenesis. IL-6 is secreted by a variety of cells
including lymphocytes, macrophages and smooth muscle cells, so much so that IL-6 is also
considered a myokine (1). The role of IL-6 in homeostasis is mediated through the classicsignaling pathway, whereas pathology-associated responses are mediated by IL-6 trans-signaling
(2). IL-6 association with the membrane-bound IL-6 receptor alpha subunit (mIL-6Rα) is referred
to as the “classic-signaling” pathway, whereas with the soluble IL-6R (sIL-6R) is called “transsignaling”. Classic IL-6 signaling is essential for defending the host against bacterial infections,
and mediates the activation of anti-inflammatory and regenerative epithelial pathways (3). In
contrast, enhanced IL-6 trans-signaling is observed in chronic inflammatory disorders such as
Crohn’s disease, atherosclerosis and rheumatoid arthritis (3,4)
IL-6 binding to the mIL-6Rα on target cells is of low affinity (5). Once IL-6 and mIL-6R
have bound, this complex binds to the signal-transducing membrane glycoprotein 130 (gp130)
to form a high-affinity, functional hexameric receptor complex of two IL-6, IL-6R, and gp130
initiating intracellular signaling via the janus kinase/signal transducer and activator of
transcription (JAK/STAT) pathway (6). Whereas robust mIL-6R expression is limited to
neutrophils, naïve T cells and hepatocytes, gp130 is ubiquitously expressed (7). The receptor
gp130 has no affinity for IL-6, making cells that lack mIL-6R unresponsive to IL-6. Therefore,
classical signaling involves IL-6 binding to mIL-6R only in lymphocytes and hepatocytes. IL-6R
can be shed from mIL-6R-expressing cells through receptor cleavage or produced by alternative
RNA splicing (8). This soluble form of IL-6 receptor (sIL-6R) has been found in urine and blood
(9) and binds with IL-6 with the same affinity as the mIL-6R (10). Again, this form of IL-6
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signaling (trans-signaling) relies upon the formation of an IL-6/sIL-6R complex in solution,
which binds to membrane gp130, activating the same downstream JAK/STAT signaling as does
the classic IL-6 signaling pathway (11,12). A soluble form of gp130 has also been detected in the
circulation (13), however, unlike sIL-6R, sgp130 has been found to be produced solely from
alternatively spliced mRNA and inhibits trans-signaling by complexing with IL-6/sIL-6R (14). In
summary, although classical IL-6 signaling appears to regulate the important homeostatic
functions of IL-6, trans-signaling has been discovered to contribute to chronic inflammatory
responses (7).
Increases in lung and serum IL-6 have been associated with pulmonary hypertension
(PH) (15). Our group (16) and another study (17) has shown a rapid rise in lung IL-6 mRNA
levels following exposure of mice to hypoxia, peaking at 24 hours and remaining elevated for a
week. Consistent with the increase in lung IL-6 mRNA, IL-6 immuno-labeling is increased in the
medial layer of pulmonary arteries of mice exposed to 5 days of CH compared to normoxic
controls (17). Interestingly, lung IL-6-overexpressing transgenic mice develop spontaneous PH
with significant vascular remodeling and perivascular infiltration of T-cells but not B-cells, not
due to hypoxia, indicating a close association between IL-6 levels and lung pathology (18). A
study relying on IL-6 knockout (KO) mice has demonstrated a central role for IL-6 in the
development of chronic hypoxia (CH)-induced PH (17). The study showed that IL-6 KO mice
exhibit less severe PH through decreased right ventricular (RV) hypertrophy and a lower right
ventricular systolic pressure (RVSP) as compared to wild-type (WT) mice following exposure to
CH. However, it is unclear whether IL-6 was acting through the classic or the trans-signaling
pathway. Therefore, the present study tested the hypothesis that IL-6 trans-signaling contributes
to CH-induced PH by promoting pulmonary arterial remodeling. Addressing this hypothesis has
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clinical implications because specific inhibition of IL-6 trans-signaling should only block the
pro-inflammatory effects of IL-6 without inhibiting its important homeostatic properties.

Keywords: soluble IL-6 receptor; pulmonary arterial smooth muscle; migration
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Introduction
Interleukin 6 (IL-6) is generally a pro-inflammatory, pleiotropic cytokine (17).
Furthermore, IL-6 is secreted by a variety of cells including lymphocytes, macrophages and
smooth muscle cells, so much so that IL-6 is also considered a myokine (22). Having a wide range
of biological effects, including regulation of the immune system, nervous system, liver
regeneration and metabolism, IL-6 signaling is tightly controlled (12). L-6 binds the membranebound IL-6 receptor (IL-6R) alpha subunit on target cells with relatively low affinity (29). Once
IL-6 and IL-6R have bound, this complex binds to the signal-transducing membrane glycoprotein
130 (gp130) to form a high-affinity, functional hexameric receptor complex of two IL-6, IL-6R,
and gp130 initiating intracellular signaling via the Janis kinase/signal transducer and activator of
transcription (JAK/STAT) pathway (30).

Whereas robust IL-6R expression is limited to

neutrophils, naïve T cells and hepatocytes, gp130 is ubiquitously expressed (27). The receptor
gp130 has no affinity for IL-6, making cells that lack membrane IL-6R receptor unresponsive to
IL-6. Therefore, two forms of IL-6 signaling exist. Classical signaling involves IL-6 binding to
membrane-bound IL-6R on target cells, such as lymphocytes or hepatocytes. IL-6R can be shed
from IL-6R-expressing cells through receptor cleavage or produced by alternative RNA splicing
(1). This soluble form of IL-6 (sIL-6R) has been found in urine and blood (25) and binds with IL6 with the same affinity as the membrane-bound IL-6R (28). This form of IL-6 signaling is called
IL-6 trans-signaling, and relies upon the formation of an IL-6/sIL-6R complex in solution, which
binds to membrane-bound gp130, activating downstream signaling, including JAK/STAT,
phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinases (MAPK) and Src/Yesassociated protein (10, 33). A soluble form of gp130 has also been detected in the circulation (23),
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however, unlike sIL-6R, sgp130 has been found to be produced solely from alternatively spliced
mRNA (3). Although classical IL-6 signaling appears to regulate the important homeostatic
functions of IL-6, trans-signaling has been discovered to contribute to chronic inflammatory
responses (27).
Human vascular smooth muscle cells express very low levels of IL-6R under basal
conditions, and therefore do not respond well to stimulation with IL-6 (18). This study
demonstrated that the treatment of smooth muscle cells with exogenous IL-6/sIL-6R resulted in a
significant up-regulation of gp130 mRNA and protein expression on the cell surface. This increase
in gp130 was associated with an increase in IL-6 secretion, contributing to a potential feed-forward
autocrine loop.
Increases in lung and serum IL-6 have been associated with pulmonary arterial
hypertension (11). Our group and others have shown a rapid rise in lung IL-6 following exposure
of mice to hypoxia, with IL-6 mRNA levels peaking at 24 hours and remaining elevated for a week
(20, 31). IL-6 contributes to distal pulmonary arterial remodeling, concentric wall thickening,
plexiform lesions, and the recruitment of inflammatory cells in mice exposed to hypoxia (36).
Interestingly, IL-6-overexpressing transgenic mice developed spontaneous pulmonary vascular
remodeling, not due to hypoxia, indicating a close association between IL-6 levels and lung
pathology. Experiements relying on IL-6 knockout (KO) mice have demonstrated a central role
for IL-6 in the development of chronic hypoxia (CH)-induced pulmonary hypertension (PH) (31).
The study shows that IL-6 KO mice exhibit less severe PH through decreased right ventricular
(RV) hypertrophy and a lower right ventricular systolic pressure (RVSP) as compared to wild-type
(WT) mice following exposure to CH. However, it is unclear whether IL-6 was acting through the
classic or the trans-signaling pathway. Therefore, the present study tested the hypothesis that IL-6
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trans-signaling contributes to CH-induced PH by promoting pulmonary arterial remodeling.
Addressing this hypothesis has clinical implications because specific inhibition of IL-6 transsignaling should only block the pro-inflammatory effects of IL-6 without inhibiting its important
homeostatic properties.

Methods
Animals
C57BL/6 mice (male, 25-28 g; The Jackson Laboratory) were used in these studies.
Protocols were approved by the Institutional Animal Care and Use Committee of the University
of New Mexico Health Sciences Center.
Chronic hypoxia exposure
Mice exposed to CH were housed in a hypobaric chamber (~380 mmHg, 5 or 21 days).
Control mice were housed at ambient barometric pressure (normoxia, N; ~630 mmHg,
Albuquerque, NM).
Assessment of right ventricular systolic pressure and right ventricular hypertrophy
Peak right ventricular systolic pressure (RVSP) was assessed in isoflurane-anesthetized
mice as previously described (26). An upper transverse laparotomy was performed to expose the
diaphragm. A 25-gauge needle, connected to a pressure transducer (model P23 XL, Spectramed),
was inserted into the right ventricle (RV) via a closed-chest trans-diaphragmatic approach, and the
output amplified by a Gould Universal amplifier. All data were recorded, and heart rate was
calculated with a computer-based data acquisition system (AT-CODAS, DATAQ Instruments).
After collecting hemodynamic data, the heart was isolated and the atria and major vessels were
removed. The RV was dissected from the left ventricle (LV) and septum (S). RV hypertrophy was
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expressed as the percentage ratio of RV to left ventricle plus septum (LV+S) weight and RV to
body weight (BW).
Circulating and Lung Levels of sIL-6R and sgp130
IL-6, sIL-6R and sgp130 were measured in heparinized plasma and the supernatant of lung
digests (20) using a Milliplex Map Kit (EMD Millipore) following the manufacturer’s
recommendations.
Vascular Morphometry
Pulmonary arterial remodeling (<150 µm outer diameter) was assessed using a
modification of previously published methods (5). After collection of hemodynamic data, the lungs
were perfused via the RV with ~5 ml of modified physiological saline solution (HEPES-PSS, 134
mM NaCl, 6 mM KCl, 1 mM MgCl2, 10 mM HEPES, 2 mM CaCl2, 0.026 mM EDTA, and 10
mM glucose) containing heparin, 4% albumin (Sigma) and 10−4 M papaverine (Sigma), at 20
mmHg to maximally dilate and flush the circulation of blood. The heart, lungs and trachea were
removed in block. The right lobes were tied off, removed and preserved in RNA Later. The left
lobe of the blood-cleared lung was fixed in 4% paraformaldehyde (Polyscience, Warrington, PA)
in phosphate-buffered saline (PBS) fixative.
Lung sections (5 μm) were stained with rabbit anti-smooth muscle α-actin (Abcam
Ab5694, Cambridge, MA) antibody or rabbit IgG control (negative) followed by DyLight 549donkey anti-rabbit (Thermo Fisher Scientific) (20). Sections were examined using a 20 or 40X
objective on a Zeiss Axiovert 200M scope, and images acquired with a Cool Snap EZ camera
using NIS-Elements F 3.0 software. Images were analyzed with Image J (NIH, Bethesda, MD).
Vessels sectioned at oblique angles were excluded from analysis. The analysis was performed in
arteries with less than <150 μm outer diameter. Approximately 10 arteries/animal were analyzed.
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Arterial wall thickness was calculated according to the following equation: % wall thickness =
[(external diameter – luminal diameter)/external diameter] x 100. Diameters were calculated from
the measured circumferences
Pulmonary artery smooth muscle cell [Ca2+]i, migration, confluency and proliferation assays
Primary pulmonary arterial smooth muscle cell (PASMC) cultures were established and
cells authenticated as previously described (13, 24). PASMCs were plated on gelatin-coated dishes
and cultured in Smooth Muscle Cell Medium (Cell Biologics) containing 10% fetal bovine serum
and antibiotic-antimycotic solution in a humidified atmosphere of 5% CO2-95% air at 37°C.
Before experiments, PASMCs were cultured for at least 48 hr in serum-free smooth muscle cell
medium containing insulin, EGF, hydrocortisone, L-glutamine, antibiotic-antimycotic solution
(M2268SF Cell Biologics).
Intracellular Ca2+ was measured in cells incubated at room temperature with HEPES-PSS
containing the cell-permeable ratiometric Ca2+-sensitive fluorescent dye fura 2-acetoxymethyl
ester (fura 2-AM; 2 µM; Life Technologies) and 0.02% pluronic acid (Life Technologies). Fura 2AM-loaded cells were alternately excited at 340 and 380 nm at a frequency of 10 Hz with an
IonOptix Hyperswitch dual-excitation light source and the respective 510 nm emissions were
collected with a photomultiplier tube (F340/F380). After subtracting background fluorescence,
emissions ratios were calculated with Ion Wizard software (IonOptix) and recorded continuously
throughout the experiment.
Migration was determined by using a WoundMaker (Essen Bioscience) to produce
homogenous, 700-800 µm wide scratch wounds on a confluent monolayer of PASMC.
Cell proliferation was, in part, assessed by determining the confluency of the culture over
time, divided by the initial confluency. Images were captured every 2 hours over a period of 60
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hours. Proliferation was also measured using a Click-IT EdU microplate assay (Invitrogen,
C10214). The assay determines cell proliferation by measuring the amount of EdU (5-ethynyl-2’
deoxyuridine, a thymidine analogue in which a terminal alkyne group replaces the methyl group
in the 5 position) incorporation into DNA during cellular DNA replication. The terminal alkyne
group was detected with fluorescent azides using the Click-IT chemistry.
RT-PCR
Total lung RNA was extracted using Direct-zol (Zymo Research) and reverse transcribed
to cDNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies). The
Roche Universal Probe Library System was used for real- time detection of gp130 (5’
cccatgggcaggaatataga, 3’ cataatccaagattttcccattg, probe 97) and ACTB as a reference gene (5’
ctaaggccaaccgtgaaaag, 3’ accagaggcatacagggaca, probe 64). The normalized gene expression
method (2-ΔΔCT) was used for relative quantification of gene expression using pooled samples as
the calibrator (34).
Statistics
Results were expressed as the mean ± standard error. Statistical significance was tested at
the 95% (p<0.05) confidence level using an unpaired t-test or two-way ANOVA followed by
Student-Newman-Keuls post-test.

Results
Components of the IL-6 Trans-signaling pathway are altered by chronic hypoxia

IL-6 trans-signaling is tightly controlled through the concentrations of sIL-6R and IL-6
(27). Under normal (non-inflammatory) conditions, the levels of sIL-6R and sgp130 are roughly
1000 times higher than IL-6 levels (27). This, then, implies that once IL-6 is secreted, it forms the
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IL-6/sIL-6R complex, and this complex is neutralized by sgp130. Only under conditions in which
IL-6 concentrations exceed that of sIL-6R, or under reduced levels of sgp130, can IL-6 act on
target cells, such as in sepsis (27, 41). Therefore, we examined the levels of these three molecules
in the plasma and lung digest of mice exposed to normoxia and CH. IL-6 levels were below the
limit of detection in plasma samples. There was no significance difference in IL-6 levels in the
supernatant of lung digests from mice exposed to normoxia vs. CH (data not shown). In addition,
there was no difference in plasma (Figure 1A) or lung digest (data not shown) sIL-6R levels
between mice exposed to 5 days of CH or normoxic controls. Interestingly, there was a significant
decrease in sgp130 in the plasma of mice exposed to CH, as compared to normoxia (Figure 1B)
but no differences in lung sgp130 levels between groups (data not shown). As expected, the ratio
of sIL-6R to sgp130 was increased in plasma from CH mice compared to controls (Figure 1C).

IL-6 Trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension
To determine the role of IL-6 trans-signaling on CH-induced PH, we used sgp130Fc (R&D
Systems, Minneapolis, MN). sgp130Fc is an Fc-dimerized version of sgp130, which specifically
blocks IL-6 trans-signaling and is highly efficacious in diverse models of chronic inflammation
(6, 15, 33). Importantly, dimerization increases the efficacy of blocking signaling via IL-6/sIL-6R
by a factor of 10-100 compared with monomeric sgp130 (15). When IL-6 is not elevated,
sgp130Fc has no effect on classic IL-6 signaling, yet disrupts IL-6 trans-signaling making it an
effective tool in dissecting the contribution of classic vs. trans-signaling in various physiologic
responses (27). Therefore, mice were given sgp130Fc (0.5mg/kg twice per week i.p.) or vehicle
(saline) control, and exposed to either CH or normoxia for 21 days. Mice treated with vehicle
exhibited the expected significant increase in RVSP following CH, while mice receiving sgp130Fc
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Figure 1. sgp130 plasma levels are decreased following exposure to CH. Mice were exposed
to CH or normoxia for 5 days. Plasma levels of sIL-6R (A), sgp130 (B), ratio of sIL-6R/sgp130
(C), and lung gp130 mRNA (D) (fold change from calibrator). Values are means ± SEM;
n=6/group, *p<0.05; analyzed with t-test.
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demonstrated a significantly attenuated increase in RVSP as compared to vehicle control mice
(Figure 2A). Similar results were seen with regard to RV hypertrophy (Figure 2B) and % arterial
wall thickness (Figure 2C). Treatment of mice with sgp130Fc did not affect the polycythemic
response to CH (Figure 2D.
It is generally thought that IL-6 trans-signaling is largely responsible for the proinflammatory actions of IL-6, while IL-6 classical-signaling is important for organism homeostasis
and the cytokine’s regenerative properties (27). To elucidate the inflammatory properties and
effects of IL-6 trans-signaling on the lung vasculature following exposure to CH, we exposed mice
to CH for 5 days while treating the mice with either vehicle (saline) or sgp130Fc. We found again
that even short (5 day) exposure of mice to CH leads to perivascular infiltration of T cells in lung
sections, as measured using immunohistochemistry to detect the T cell co-receptor, thus providing
a pan-T cell CD3 marker (Figure 3) (20). Interestingly, mice receiving sgp130Fc to disrupt IL-6
trans-signaling demonstrated a marked reduction in perivascular T cells (Figure 3).

IL-6 Trans-signaling enhances PASMC migration but not proliferation
To determine whether IL-6 trans-signaling contributes to CH-induced alterations PASMC
cell migration and proliferation, mouse PASMC (mPASMC) were cultured in differentiation
media in the presence or absence of IL-6 (500 ng/ml) and sIL-6R (500 ng/ml) and grown to a subconfluent density. Cell culture confluency was not affected by treatment with IL-6/sIL-6R (Figure
4A) nor was the proliferation rate of the cells assessed by EdU incorporation to DNA (Figure 5B).
IL-6 was pre-incubated with sIL-6R or sIL-6R plus sgp130Fc at 37°C before adding it to the cells.
The contribution of IL-6/sIL-6R signaling to PASMC migration was investigated using a
scratch wound assay (19). Cells were incubated in the presence or absence of IL-6 alone, sIL-6R
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Figure 2. Inhibition of IL-6 trans-signaling attenuates CH-induced increases in RV systolic
pressure, RV hypertrophy, and pulmonary arterial remodeling with no effect on
hematocrit. (A) Right ventricular systolic pressure (RVSP), (B) Fulton’s index (right ventricle
(RV)/left ventricle plus septum (LV+S) weight), (C) % wall thickness of α-smooth muscle actinstained pulmonary artery sections with external diameters <150 µm, and (D) hematocrit from
mice that received vehicle (saline) or sgp130Fc during exposure to normoxia or CH for 21 days.
Representative images of α-smooth muscle actin-stained pulmonary artery sections. Values are
means ± SEM; *p<0.05 vs. normoxia vehicle, #p<0.05 vs CH vehicle n=6/group; analyzed with
ANOVA and individual groups compared with the Student-Newman-Keuls test.
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alone, the IL-6/sIL-6R complex, or the combination of IL-6/sIL-6R and sgp130Fc (10 µg/ml).
mPASMC incubated in the presence of IL-6/sIL-6R showed a significant increase in cell migration
compared to cells grown in control media (mPASMC differentiation media), cells incubated with
IL-6 alone, sIL-6R alone or IL-6/sIL-6R plus sgp130 Fc (Figure 4C).
In the process of IL-6 trans-signaling, gp130 forms a homodimer, recruiting Jak/STAT
proteins(12), specifically STAT3, and initiating downstream signaling. Therefore, to verify that
STAT3 activation contributes to IL-6/sIL-6R-induced enhanced mPASMC migration, cells were
pre-incubated with STAT3 Inhibitor III (1 µM, WP 1066, Santa Cruz Biotechnology) and the rate
of cell migration was measured as described above (Figure 5D). In fibroblasts, it has been shown
that IL-6 trans-signaling also increases [Ca2+]i but this has not been determined in PASMC (35).
Therefore, to further address the contribution of [Ca2+]i to IL-6 trans-signaling, cells were
incubated with IL-6/sIL-6R in the presence of 5 µM BAPTA AM (Thermo Fisher), 10 µM
cyclopiazonic acid (CPA, Sigma-Aldrich) and 50 µM diltiazem (Sigma-Aldrich). Intracellular
Ca2+ chelation together with inhibition of Ca2+ influx through voltage-dependent Ca2+ channels
and inhibition of endoplasmic reticulum Ca2+-ATPase prevented IL-6/sIL-6R-induced mPASMC
migration (Figure 4D). Consistent with this finding, IL-6/sIL-6R caused a significant increase in
the change in fura-2 fluorescence ratio from baseline compared to vehicle (Figure 4E).
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Figure 3. Blocking IL-6 trans-signaling attenuates CH-induced perivascular T cell
infiltration. Summary of the number of perivascular CD3+ cells (T cells) from mice exposed to
5 days of normoxia or CH, treated with or without sgp130Fc. The perivascular region was
defined as external to the vessel media, and internal to vessel adventitia between the two layers.
Values are means ± SEM; *p<0.05 vs. normoxia vehicle, #p<0.05 vs normoxia sgp130, n = 6
mice/group; analyzed with ANOVA and individual groups compared with the Student-NewmanKeuls test.
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Figure 4. IL-6/sIL-6R enhances cell migration and [Ca2+]i but not proliferation. (A)
Confluency of mPASMC was determined using an IncuCyte system in cells cultured in
differentiation media in the presence or absence of IL-6/sIL-6R complex. (B) Edu incorporation
in cells treated as in A. (C) Scratch wound assay in mPASMC differentiated as in (A). Wound
closure was tracked over time in the presence or absence of IL-6/sIL-6R ± sgp130. (D) same as
C but with IL-6/sIL-6R ± STAT3 inhibitor or in the absence of [Ca2+]i. (E) Change in fura-2
fluorescence ratio (F340/F380) in cells incubated in the absence (vehicle) or presence of IL6/sIL-6R. Representative traces are shown on the right. Vertical line indicates the addition of
vehicle or IL-6/sIL-6R. Values are means ± SEM; *p<0.05 vs. control n=3-8/group; analyzed
with repeated measures ANOVA.
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Discussion
In this study, we have demonstrated an effect of CH exposure in mice to disrupt the balance
between plasma levels of sIL-6R and sgp130. Inhibition of IL-6 trans-signaling with sgp130Fc
attenuated indices of CH-induced PH, including elevated RVSP, RV remodeling and pulmonary
arterial remodeling. Furthermore, CH-induced perivascular T cell infiltration was inhibited in
mice treated with sgp130Fc. Finally, the IL-6/sIL-6R complex enhanced PASMC migration, but
not proliferation, through a pathway that requires increases in [Ca2+]i and activation of STAT3.
Taken together, this study reports the novel finding that IL-6 contributes to CH-induced PH
through the trans-signaling pathway.
It has been previously demonstrated that cytokines contribute to the pathogenesis of PH in
both human and animal studies. IL-6 has been implicated in PH in multiple studies, from patients
with chronic obstructive pulmonary disease (COPD) showing elevated levels of plasma IL-6 (4),
to several experimental studies showing an active role for IL-6 on pulmonary vascular remodeling
and hypoxic PH in mice (36). Furthermore, IL-6 mRNA levels have been shown to rise rapidly in
the lungs following hypoxic exposure, along with IL-6 protein. Our group, along with others have
demonstrated, via immunohistochemistry, that IL-6 levels are strongly increased in pulmonary
arterial smooth muscle cells of the vessel media (20, 31). Savele et al. further demonstrated that
hypoxia resulted in a marked increase in lung expression of IL-6R and gp130 (31). In this study,
we found no changes in lung gp130 mRNA expression or lung protein levels of sgp130, the latter
of which acts as a natural inhibitor of IL-6 trans-signaling by binding the IL-6/sIL-6R in solution,
thereby preventing the complex from interacting with gp130 on the cell surface. In contrast, we
observed a significant decrease in circulating sgp130 levels with no change in plasma sIL-6R.
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Together, these finding suggest that IL-6 trans-signaling is elevated after CH exposure based on
locally increased levels of IL-6 and decreased circulating sgp130.
Therapeutic monoclonal antibodies are currently being used to treat patients, and these
antibodies bind various sites on the IL-6 signaling complex, interfering with IL-6 signaling (39).
For example, Tocilizumab (Actemra, Hoffmann-La Roche), an anti-human IL-6R monoclonal
antibody, blocks the interaction of IL-6 and IL-6R by binding a specific site on the receptor,
whereas olokizumab (R-Pharm-UCB), an anti-human IL-6 monoclonal antibody, blocks hexamer
formation by targeting another specific site on IL-6R. These antibodies are believed to provide
blockade of IL-6 signaling in an indiscriminate way, i.e., both classic and trans-signaling. Recent
data support the hypothesis that these two IL-6 signaling pathways lead to different biological
sequela. The contribution of trans-signaling to disease has recently been advanced through
development of the engineered variant of soluble gp130, sgp130Fc. Studies using sgp130Fc have
advanced our understanding of trans-signaling’s contribution to disease (15).
Administration of an antibody against IL-6R attenuates CH-induced PH in mice but again
this antibody does not discriminate between the membrane-bound and the soluble form of the IL6R, blocking both classic and IL-6 trans-signaling (7, 8). In the present study, we explored the
direct effect of IL-6 trans-signaling using the specific inhibitor sgp130Fc. Using this novel
approach, we found that administration of sgp130Fc significantly attenuated CH-induced increases
in RVSP and right ventricular hypertrophy, supporting a contribution of IL-6 trans-signaling to
CH-induced PH.. PH can result from exposure to high altitude or chronic lung diseases that lead
to global hypoxia, such as COPD and interstitial lung diseases. Over time, alveolar hypoxia likely
contributes to “fixed” components of PH, such as structural remodeling of the pulmonary arterial
bed leading to increased arterial resistance (37). Pulmonary arterial remodeling is characterized by
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thickening of the muscular medial layer of arteries and the extension of muscle into small
previously non-muscular pre-capillary arterioles, likely mediated by PASMC proliferation and
migration (38, 40). Consistently, sgp130 administration also attenuated CH-induced pulmonary
arterial remodeling.
Other work examining the direct effect of IL-6 on vascular smooth muscle cell (VSMC)
migration and proliferation have demonstrated that IL-6 stimulates VSMC migration but not
proliferation (42). This study showed that IL-6 caused the assembly of actin stress fibers, driving
VSMC migration based on reorganization of the cytoskeleton. More recent work looking
specifically at the migration and proliferation of human PASMC demonstrated a similar response
to IL-6 regarding cell migration and proliferation (32). The addition of IL-6 to the cells promoted
migration, however, when the PASMC were cultured with IL-6 combined with sIL-6R, the effects
on migration were even further enhanced, while proliferation was unchanged.
Our results are in close agreement with these previous findings in cultured human PASMC.
However, we found that primary mPASMC do not respond to IL-6 alone. IL-6 must be complexed
with sIL-6R to enhance migration of mPASMC. In addition, this effect was completely blocked
by the addition of sgp130 suggesting that the mIL-6R is either not expressed or not active in
mPASMC. These previous findings, in combination with our own data, indicate that IL-6 exerts
direct pro-migratory effects on PASMC.
IL-6 bioactivity has been tightly linked to the localization and migration of T cells. In the
current study, we examined the perivascular accumulation of CD3+ T cells following CH with or
without IL-6 trans-signaling inhibition. We found that the recruitment of T cells to the perivascular
space was largely dependent upon intact IL-6 trans-signaling, which is in accordance with previous
studies showing that IL-6 trans-signaling plays an important role in chemokine release. Our data
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indicate that IL-6, being secreted from the pulmonary arterial smooth muscle cells following CH,
acting largely through trans-signaling, may lead to enhanced chemokine-mediated trafficking of T
cells to the perivascular space.
Interestingly, T cells, upon activation, greatly reduce IL-6R expression on their surface,
indicating that classical IL-6 signaling is required for initial activation and polarization of naïve T
cells, yet IL-6 trans-signaling may play a crucial role in maintaining an ongoing pro-inflammatory
state mediated by TH17 cells (14). In addition, IL-6 governs T cell infiltration by regulating the
secretion of various chemokines and expression of chemokine receptors on CD3+ cells (21). These
studies showed that blocking IL-6 trans-signaling with sgp130 prevented chemokine release, while
leaving chemokine receptor expression unaltered. This resulted in a spg130 dose-dependent
decrease in lymphocyte migration to the site of experimentally induced active inflammation. We
have recently shown that CH leads to perivascular recruitment of CD3+ T cells to pulmonary
arteries, specifically CD3+ CD4+, IL-17+ TH17 cells (20). Given the dependence of TH17 cells on
IL-6, we were interested in examining the overall T-cell infiltration of the perivascular space
following CH (2, 9, 16, 20). Again, we observed a marked increase in perivascular T cells
following CH, which was attenuated with the inhibition of IL-6 trans-signaling. Given the
importance of trans-signaling in the tissue maintenance of TH17 cells (14) it would seem likely
that the IL-6 produced by smooth muscle cells following CH could contribute to a TH17-mediated
pro-inflammatory environment. In addition to the previously demonstrated effect of IL-6 on
PASMC migration, TH17 cells may contribute to PASMC proliferation through the production of
IL-21, M2 macrophage skewing and subsequent CXCL12 production, directly promoting PASMC
proliferation (8). Furthermore, since a source for sIL-6R is activated T cells, the pro-inflammatory
environment established by CH-induced IL-6 expression by PASMC could activate and polarize
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naïve CD4+ T cells, causing the release of further sIL-6R, allowing for the increased recruitment
and maintenance of previously activated memory and tissue-resident pro-inflammatory TH17 cells.
In summary, this study demonstrates that the inhibition of IL-6 trans-signaling results in
an attenuated increase in RVSP and cardiac remodeling as compared to mice with un-inhibited IL6 trans-signaling. We have also demonstrated that IL-6 trans-signaling contributes to enhanced
PASMC migration, as demonstrated using IL-6/sIL-6R complex in culture media, as compared to
IL-6 or sIL-6R alone. Furthermore, we also demonstrated that the inhibition of IL-6 trans-signaling
lead to a decrease in PASMC migration but not proliferation. Therefore, we conclude that IL-6
trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension, at least partially
though enhanced PASMC migration, likely through increased muscularization of previously nonmuscluarized distal pulmonary arterioles.
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Chapter 4 – Discussion

The overall objective of these studies was to identify the contribution of immune cells to
chronic hypoxia (CH)-induced pulmonary hypertension (PH) and to elucidate mechanism of
interleukin-6 (IL-6) involvement. The major findings from these studies are: 1) the adaptive
immune system, specifically CD4+ T helper 17 (TH17) cells, contribute to CH-induced PH; 2)
CH leads to an increase in TH17 cells in the perivascular space in the lungs as compared to mice
exposed to normoxic conditions; 3) the TH17-specific cytokine IL-17A enhances pulmonary
artery smooth muscle cell (PASMC) migration but not proliferation; 4) CH leads to decreasing
plasma sgp130 levels; 5) IL-6 trans-signaling contributes to CH-induced PH; and 6) IL-6 transsignaling enhances PASMC migration. From these findings, we conclude that TH17 cells, along
with IL-6 trans-signaling contribute to CH-induced PH. TH17 cells, through the production of IL17A have the potential to directly promote enhanced PASMC migration. Other groups have
demonstrated an IL-6-dependent accumulation of TH17 cells in the lungs following exposure to
hypoxia (22). Therefore, CH leads to an increase in lung IL-6, promoting the accumulation of
TH17 cells in the lungs. These TH17 cells produce IL-17A, leading to enhanced migration of
PASMC. In addition, the hypoxia-induced accumulation of T cells can lead to the shedding of
sIL-6R, along with a decrease in the regulatory molecule for IL-6 trans signaling, sgp130,
resulting in enhanced IL-6 trans signaling, also contributing to enhanced migration of PASMC.
These studies are significant in that they are the first to demonstrate a link between TH17 cells
and CH-induced PH. They also show, for the first time, that IL-6 trans-signaling contributes to
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CH-induced PH, likely through the IL-6 trans signaling-mediated enhancement of PASMC
migration.
The immune system is a complex network encompassing a variety of cell types, effector
mechanisms and communication methods. Immune cells have the unique ability to access nearly
all tissues of the body, and communicate over relatively short and long distances to affect the
tissues in which they reside. The activation of T lymphocytes occurs in lymphoid tissue and
generates functionally diverse subsets of T cells with the capacity to migrate to multiple tissue
sites (10). Most activated effector cells die relatively rapidly after activation but a subset of
primed T cells develop into long-lived memory cells, which persist in lymphoid and mucosal
sites. Studies in mice have demonstrated an important role for tissue-resident memory CD4+ and
CD8+ T cells in protective immunity to site-specific pathogens, like in the lung and skin (10).
Recent studies have shown that the lung, unlike other tissue such as the spleen, contains resident
memory CD4+ T cells that do not circulate (66). Evidence has shown that the lungs are a major
site of immune regulation (12). The massive surface area of the lung epithelium (500-800 square
feet (6) and the close association of an extensive capillary network for gas exchange places the
lung in a vulnerable position with regard to the external environment (12). T cells play a crucial
role in host immunity in the lungs, providing protection against a variety of various pathogens,
including viral, fungal and bacterial. The best example of the importance of T cells in the lung is
demonstrated in human immunodeficiency virus (HIV) infection. HIV targets CD4+ T cells,
resulting in the patient to progress to AIDS, which is defined either by CD4+ T cell numbers
below 200 cells per µL or by the presence of specific diseases in association with an HIV
infection. Many of these AIDS-defining illnesses are pulmonary infections, illustrating the
intimate role of T cells in the pulmonary system.
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Our studies help to highlight the interwoven nature of the pulmonary environment with
the immune system. Given the importance of pulmonary immune surveillance, the close
association between airway mucosa and the pulmonary vasculature, and the variety of cytokines
and growth factors present, it is not too surprising that a disruption to homeostasis like hypoxia
could elicit an immune response. Our studies demonstrate the complexity of the lungs, showing
that hypoxia triggers an initial pro-inflammatory response that ostensibly becomes maladaptive,
promoting tissue growth and cell migration, which leads to disease. Our initial studies
demonstrated that recombination activating gene 1 (RAG1) knock out (KO) mice, lacking
adaptive immune cells, show attenuated increases in pulmonary hypertensive measures of
disease, such as right ventricular systolic pressure (RVSP) and vascular remodeling. This would
indicate that adaptive immune cells, either T or B cells, represent the initial trigger or effector of
pulmonary arterial change following CH. What we can tell from these studies is that the adaptive
immune cells play an important role in CH-induced PH. When these cells were given back, and
the RAG1 KO mice were reconstituted, the CH-induced PH was present, similar to wild-type
(WT) mice. One might argue that giving isolated T cell subsets creates an artificial environment,
as immune cells often depend on signals from other immune cells for full activation and
maturation, as demonstrated by the importance of so-called CD4+ T helper cells on CD8+ and B
cell activation and maturation. A potential limitation of our study is that we did isolate and
adoptively transfer immune subsets after enrichment. However, in our studies, we found that
CD4+ T cells were both necessary, and sufficient to drive the CH-induced PH phenotype, that is,
to increase RVSP, pulmonary arterial remodeling and right ventricular (RV) remodeling seen in
WT mice. Based on the response of the adoptively-transferred CD4+ T cells, we can conclude
that CD4+ T cells, in the absence of other adaptive immune cells, contribute to CH-induced PH.
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Because CD8+ T cells and B cells are reliant upon signaling from CD4+ T helper cells, we cannot
exclude the possibility that that these cells, in concert with CD4+T cells also contribute to CHinduced PH.
It is important to note that other groups have shown a somewhat different finding with
regards to using an immune deplete host to examine the relationship between PH and the
immune system. A study conducted by Miyata et al. in 2000 demonstrated that athymic nude rats
develop severe PH following monocrotaline treatment, as compared to WT rats receiving the
same treatment (37). T cell immunodeficiency in these animals makes them specifically sensitive
to the development of severe PH, even under normoxic conditions. According to these studies,
most athymic rats simultaneously subjected to SU5416 and hypoxia together, die from PH within
3 weeks (65). Rasa Tamosiuniene and Mark Nicolls (63), in an attempt to better understand this
phenomenon, conducted studies in athymic rats, which similar to our studies, rely on the
isolation, purification and adoptive transfer of immune cell subsets to the athymic animals. Their
data show that reconstitution with total splenocyte isolates, consisting of T and B cells, prevented
the development of severe PH (63). The study went on to show that it is a CD4+ fraction,
enriched for markers of regulatory T cells (Tregs) that if lacking allows for the development of
severe PH in these athymic rats. It should be noted that there are a few major differences
between this work, and our work. First, the model of PH between the studies is different. Our
studies rely on CH, as opposed to the plant alkaloid monocrotaline or vascular endothelial
growth factor (VEGF) antagonism, such as SU5416. These models induce a disease in rodents
much more similar to PAH, resulting in pulmonary arterioles becoming occluded with
proliferating endothelial cells, surrounded by macrophages, B cells and mast cells, along with
anti-endothelial antibody deposition, and right ventricular inflammation (42). So it is quite
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appropriate to say that this is a very different model of PH, as compared to CH-induced PH.
Second, athymic animals are not as ideally and specifically immunocompromised as RAG1 KO
mice. The mutation that results in an athymic animal is a disruption to the forkhead box N1
(FOXN1) gene, crucial to the development of thymic epithelial cells (TEC). Disruption to TEC
results in a “nude” phenotype and a severe combined immunodeficiency (SCID). These animals
lack mature T cells, because the thymus is required to drive T cell differentiation, education, and
selection process, nude animals have a deficiency in mature and functional T cells (48).
However, this is considered a “leaky” SCID model, in that functional T and B cells can still be
detected, especially as the animal ages (25). Conversely, the RAG1 gene is required for proper T
and B-cell receptor production through its required effect on V(D)J recombination. Without
RAG1, T and B cells lack their receptors, and do not receive the required growth signals to
develop, and their development is arrested (38).
A central dogma of immunology is that naïve T cells do not do very much without
encountering their cognate antigen. The antigen is presented to them on major histocompatibility
complex (MHC) from either antigen presenting cells for CD4+ T cell activation, or nucleated
cells for CD8+ T cell activation (25). Central to understanding the role for the adaptive immune
system in CH-induced PH is understanding what hypoxia does to the antigenic environment of
the lung. Ours, and other groups have demonstrated that hypoxia leads to the increase of lung
interleukin-6 (IL-6) (50). At least some of the increased IL-6 in the hypoxic lung has been shown
to come from the pulmonary artery medial layer (50). Naïve T cells differentiate and activate
based on signals from their T-cell receptor (TCR) along with costimulatory signals, mostly
through CD28. Therefore, a question of central importance to these studies is the question of
antigen. If we explore a different but related field such as systemic hypertension, we can find
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evidence of immune involvement there as well. A study focusing on T cells in hypertension and
cardiovascular disease done by Guzik et al. in 2007 demonstrated a necessity of the presence of
T cells for the full development of angiotensin (Ang) II-induced hypertension in mice (20).
Similar to CH-induced PH, the activation of the adaptive immune system implies the presence of
an antigen. The possibility exists that the adaptive immune system is responding to a self-antigen
through the loss of self-tolerance, indicating that CH-induced PH could be, in part, an
autoimmune disease. Another possibility is that hypoxia may result in the formation of neoantigens which include protein oxidation, nitrosylation, adduct formation or posttranslational
modifications which result in proteins that are no longer distinguished as self (21). In support of
the loss of tolerance, a study by Dang and Pan et al. for 2011 shows that hypoxia can directly
inhibit Tregs through the binding of HIF-1 to the Treg specific transcription factor Foxp3 under
hypoxic conditions, targeting it for proteasomal degradation. Additionally, they showed that
hypoxia drives T-helper 17 (TH17) cell polarization through the effects of HIF-1 on the TH17specific nuclear receptor RAR-related orphan receptor gamma t (RORɣt) (16). Thus, HIF-1 may
represent a direct connection between hypoxia and a loss of peripheral tolerance through the
downregulation of Tregs, and the promotion of pro-inflammatory TH17 cells. We measured no
changes in Tregs in the lungs following 5 days of CH, while measuring a nearly 4-fold increase
in TH17 cells (Chapter 2, Fig. 4). We did not, however assess systemic TH17/Treg ratios, nor did
we examine time points earlier than 5 days, or prior to 21 days of hypoxia exposure. Given our
measured increase in TH17 cells following CH, our results are consistent with the previous study
identifying HIF-1 as a promoter of TH17 cell polarization (16).
As we continued our exploration of the adaptive immune system and its response to CH,
we measured the increase in lung IL-6 following exposure to CH. Therefore, because the reliance
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of TH17 cells on IL-6 is so well studied, it was a logical step to examine whether the CD4+ T
cells we had implicated were TH17 cells, as opposed to TH1 or TH2. Initially, TH17 cells were
discovered in a mouse model of autoimmune disease. The role of TH17 cells and interleukin-17
A (IL-17) in pulmonary host defense were well recognized even before TH17 cells were
identified as the primary source for IL-17 (71). Mice deficient in IL-17A have increased
susceptibility to gram-negative bacteria (71). Interestingly, new data have shown that TH17 cells
are not the only source of IL-17 in the lung. γδ T cells and newly discovered innate lymphoid
cells (ILC) type 3 are also major sources of IL-17 and IL-22 (60). Although crucial for host
defense, many studies highlight the deleterious effects of TH17 cells and associated cytokines,
such as IL-17 and IL-22. Diseases such as systemic lupus erythematosus, rheumatoid arthritis,
type I diabetes, autoimmune thyroid disorders, multiple sclerosis, myasthenia gravis, and
inflammatory bowel disease all demonstrate a central role of circulating IL-17 and increased
numbers of TH17 cells (62). IL-17 acts mainly as a promoter of the generation of proinflammatory cytokines and chemokines, leading to the attraction of neutrophils and
macrophages to the site of inflammation (26).
Interestingly, studies have examined the production of neo-antigens due to the activities
of reactive oxygen species (ROS) which are elevated in hypoxia. These studies have shown that
cryptic epitopes which are normally hidden from T cells within basement membrane hexamers of
type IV collagen are exposed following exposure to ROS (29). There is evidence that ischemia
reperfusion injury, as seen in lung transplantation, leads to the exposure of collagen V (colV)
which is considered a sequestered antigen, in that is typically immunologically “hidden” due to it
being located within tissue (24). When exposed, colV is found largely in the perivascular and
peribronchiolar tissues of the lung, which, interestingly, is where we measured the greatest
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increase in CD3+ cells following CH exposure. Studies have shown that T cell-mediated
autoimmunity to colV is a major risk factor for bronchiolitis obliterans syndrome (BOS), in
which there is a progressive airflow obstruction. This model demonstrates that through
mechanisms involving ischemia and reperfusion injury, a self-antigen becomes immunologically
exposed to cause lung disease. One could speculate that CH may lead to exposure of colV,
through mechanisms such as increased ROS, activation of tissue remodeling, matrix
metalloproteinase activation, or other mechanisms, along with a potential increase in collagen
deposition. Importantly, studies have shown that in the lung, the airway obliteration associated
with the colV BOS model depends on IL-17 (40). However, the cellular source of the IL-17
driving this fibro-obliteration, being innate or adaptive T lymphocytes, or both, is still disputed
(70). ILC have been shown to produce IL-17, and IL-22 and provide host protection and
immunity to extracellular bacteria, likely an important role in the context of the lung (2).
Importantly, however, our studies demonstrated that RAG1 KO mice were protected from the
development of CH-induced PH, and that the adoptive transfer of CD4+ T cells restored the
response to CH. ILC do not require RAG-dependent rearrangement of their antigen receptors.
This suggests that in RAG1 KO mice, it is likely that ILC are still present, making it less likely
they are central to the development of CH-induced PH (57).
As previously mentioned, immune activation and its contribution to cardiovascular
disease has been demonstrated in models of systemic hypertension. One recently demonstrated
phenomena is protein oxidation by isoketals, which are derived from free radical-mediated lipid
peroxidation of arachidonic acid (8). David Harrison’s group recently showed in two mouse
models of hypertension, treatment with either angiotensin II or deoxycorticosterone plus NaCl,
that isoketal-modified proteins accumulated in splenic dendritic cells (30). The accumulation of
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isoketal-modified proteins in dendritic cells was a consequence of oxidative stress. Oxidative
injury and inflammation are closely linked, and dendritic cells seem to play a role (30). Dendritic
cells release mediators that promote and determine T cell polarization pathways. The Harrison
group has demonstrated that systemic hypertension augmented the capacity of dendritic cells to
produce IL-1β, IL-6 and IL-23, cytokines that are known to polarize T cells to produce IL-17.
Studies from this group have shown that mice lacking IL-17A exhibit blunted hypertensive
responses to angiotensin II (33), and that the infusion of IL-17A raises blood pressure, in part by
altering activation of the endothelial nitric oxide synthase (41). Because oxidative stress is shared
between models of systemic hypertension and CH-induced PH, it is possible that there are a
variety of mechanisms that may lead to adaptive immune activation, and activation of IL-17producing cells in the lung following CH. We used SR1001, a specific inhibitor of RORγt, a key
nuclear receptor for the development of TH17 cells and production of IL-17, to demonstrate that
IL-17 contributes to CH-induced PH. We showed that mice exposed to CH and receiving
SR1001 were protected from the development of CH-induced PH compared to mice receiving
vehicle and exposed to CH. Furthermore, we demonstrated that IL-17A stimulated the migration
of PASMC, but had no effect on proliferation (Chapter 2, Fig. 11).
Γδ T cells, discovered in the mid 1980s, demonstrate a preferential localization to
mucosa. Research looking at the role of γδ T cells in the lung began in earnest when A. Augustin
and his collaborators at National Jewish Medical Research Center in Denver, Colorado, reported
that CD3+ αβ TCR- T cells were 8–20% of pulmonary lymphocytes in mice, and that these cells
increased when the mice were exposed to Mycobacterium tuberculosis (4). The γδ T cells, which
are CD3 positive and generally CD4 and CD8 negative, are the predominant T lymphocyte
populating the lungs at birth, and their proportions change as the animal ages. Interestingly,
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studies have shown that pulmonary T lymphocytes are derived from both migrants obtained from
the thymus, along with precursor T cells, which have undergone differentiation and selection in
the lung. These γδ T cells require RAG1 and RAG2 for their development, as they rely on TCR
rearrangement (54). However, the antigens that activate γδ T cells are still largely unknown, and
γδ T cells are unique in that they do not seem to require antigen processing and MHC
presentation of peptide epitopes for their activation. Interestingly, specifically for the idea of CHinduced antigen exposure, is that studies have shown that γδ T cells produce IL-17 (called γδT17
cells) , and that their activation and production of IL-17 is largely independent of T-cell receptor
activation, and is regulated through cytokine signaling, specifically IL-23 in combination with
IL-1β or IL-18 (14, 60). It has been shown that IL-6 and TGF-beta are crucial for the generation
of γδT17, indicating further that the increased lung IL-6 following CH may drive γδT17 cells in
addition to TH17 cells (17, 45). A limitation of our study is that we did not look at the γδ subsets
in the lung to determine what their contribution to CH-induced PH may be. While we did see no
difference in CD3+, CD4-, IL-17A+ T cells between normoxic and CH-exposed mice, some γδ T
cells may vary in their expression of CD4, so a more direct staining protocol specific for γδ T
cells might be warranted.
Another intriguing possibility for the activation of the adaptive immune system in CHinduced PH is that hypoxia, through the production of a pro-inflammatory environment by
production of IL-6 by smooth muscle cells is enhancing the basal level of immune activation to
normal lung antigens, such as inhaled particles. Therefore, hypoxia promotes a pro-inflammatory
environment, leading to a globally enhanced inflammatory reaction from the adaptive immune
system, furthering the inflammation leading to CH-induced PH. That is, the antigen may not be
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specific to hypoxia, but it is the heightened immune reaction to the normally present antigens
that furthers the inflammation.
IL-6 is a cytokine with a variety of functions in various tissues, and can induce both proand anti-inflammatory responses (69). Typically, only a small amount of IL-6, in the range of
picograms, can be detected in healthy humans. IL-6 is rapidly and greatly up-regulated in just
about all pathophysiologic states (69). IL-6 elicits intracellular signaling after binding to the
membrane bound IL-6 receptor (IL-6R) which is expressed on hepatocytes and some leukocytes.
The signaling requires the membrane-bound receptor glycoprotein 130 (gp130). The second
signaling pathway, trans-signaling, IL-6 binds the soluble forms of the IL-6R (sIL-6R), and the
IL-6/sIL-6R complex can activate all cells due to the uniform expression of gp130 on all cells.
There are a handful of studies implicating IL-6 in PH due to CH, but for the first time, our
studies show that IL-6 trans signaling is likely the signaling pathway being utilized in CHinduced PH. Given that IL-6R expression is limited to lymphocytes and hepatocytes, it is
interesting that IL-6 has such a widespread effect. This is, of course, explained by transsignaling, and the presence of gp130 on all cells. This fact demonstrates why trans-signaling
might be considered so important. That a picogram quantity of a cytokine might affect cell types
throughout the body based on the presence of IL-6/sIL-6R complex in addition to the widespread
expression of the target, gp130, also illustrates how important and complex trans signaling
regulation may be. Since the sgp130 (soluble form of gp130) is known to inhibit the IL-6/sIL-6R
induced trans-signaling, it represents an ideal pharmacologic target for IL-6 signaling (28).
Multiple groups, including our own, have demonstrated that hypoxia leads to IL-6
production from the pulmonary artery (Chapter 2, fig. 3B). IL-6 expression depends largely on
the nuclear factor kappa-light chain-enhancer of activated B cells (NF-𝜅B) (32). The seminal
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discovery that hypoxia can induce the activation of NF-𝜅B was made in 1994 (31). These early
studies showed that hypoxia-induced NF-𝜅B was mediated by phosphorylation of a tyrosine
residue in I𝜅Bα. More recent studies have demonstrated a contribution from the
calcium/calmodulin-dependent kinase (CaMK2) in this response (15). In CH, there is an increase
in intracellular calcium of the PASMC (reviewed in chapter 1). This increase in intracellular
calcium could lead to activation of NF-𝜅B and subsequent IL-6 production from PASMC. Given
that the IL-6 receptor expression is limited to hepatocytes and lymphocytes, cells of the
pulmonary vasculature are dependent upon free serum sIL-6R to bind the gp130 on the
pulmonary arterial smooth muscle cells, and potentially the endothelial cells, as gp130
expression is ubiquitous. The pro-inflammatory components of IL-6 are thought to be mediated
largely by trans-signaling. sIL-6R is produced by cells which express the IL-6 receptor on their
membrane surface and through protein cleavage and alternative splicing, these cells produce sIL6R. The membrane-bound enzyme ADAM17 is responsible for the majority of sIL-6R
production through surface protein cleavage. There is some evidence that ADAM17 is activated
by hypoxia (11). Therefore, CH could lead to both an increase in available IL-6, along with
increased sIL-6R cleavage from lung-resident lymphocytes. These two molecules interact with
high-affinity to form a IL-6/sIL-6R complex, which interacts with gp130 in the membrane of
cells to elicit a STAT3 and calcium-dependent signaling cascade (chapter 3, figure 4 and (49).
IL-6 has a variety of effects both anti and pro-inflammatory and evidence continues to
mount that IL-6 trans-signaling is responsible for the later. When activated, CD4+ T cells show a
decrease in their surface IL-6R expression (27). This is mostly evident in recent studies of T cell
biology in which IL-6 trans-signaling was shown to affect T cell activation, recruitment and
apoptotic clearance (3, 36). Recent studies show that in addition to the initial IL-6/TGF-B
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stimulation of T cells leading to activation, the continued inflammatory activity of polarized
TH17 cells depends upon IL-6. Specifically, these studies demonstrate that the continued activity
of TH17 cells depends on IL-6 trans signaling (27). Therefore, CH leads to increased IL-6
production from the pulmonary vasculature and TH17 cells depend on trans-signaling to maintain
an ongoing pro-inflammatory state.
Since only a handful of cells have been shown to express IL-6R, and thus have the
potential to produce it, the source of the sIL-6R in the lung is likely T cells. As mentioned, once
activated, T cells release IL-6R as sIL-6R. CH leading to the enhanced production of IL-6 from
the pulmonary vasculature, in conjunction with CH-induced neoantigen formation, may lead to
the activation and TH17 cell-polarization of naïve T cells, which when activated release sIL-6R
either through membrane cleavage or alternative splicing into the lung environment, where it
interacts with available increased levels of IL-6. The IL-6/sIL-6R complex can then bind with
gp130 on the surface of PASMC leading to intracellular signaling mediated by signal transducer
and activator of transcription 3 (STAT3). It would be valuable to determine whether T cells
polarized under TH17 conditions produce more or less siL-6R than T cells polarized to other T
helper subsets. If TH17 cells produce sIL-6R it would potentially establish a paracrine/autocrine
feed-forward pro-inflammatory state that would be difficult to control, although the production
of sgp130 is one potential mechanism to disrupt this signaling by blocking the interaction of IL6/sIL-6 complex from interacting with gp130, thus inhibiting STAT3 signaling.
STAT3 has been shown to be important for cell proliferation, migration and antiapoptosis, indispensable cell processes for CH-induced pulmonary arterial remodeling and PH
(44, 67, 72). STAT3 signaling could theoretically lead to PASMC proliferation and migration
through a variety of mechanisms. Several STAT binding sites have been identified within the
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promoter regions of NFATc2(13), potentially increasing the expression of NFATc2, which,
when activated, has been shown to lead to down-regulation of Kv1.5 in PAH patients or rats
receiving monocrotaline, a model of PAH, resulting in increased intracellular Ca2+ and K+
concentrations, leading to increased PASMC contraction, proliferation, migration and resistance
to apoptosis (7). Although STAT3 is implicated in pulmonary arterial hypertension, more work
is required to further explore a role for STAT3 in CH-induced PH (44).
The hallmarks of PH are sustained vasoconstriction and vascular remodeling.
Remodeling of pulmonary arteries is characterized by thickening of the intimal and/or medial
layer of muscular vessels and the appearance of cells expressing smooth muscle specific markers
in distal arterioles, or the muscularization of previously non-muscularized vessels(59, 68). Mice
exposed to CH develop muscularization of distal vessels along with thickening and functional
stiffening of proximal, conduit arteries (59). The remodeling seen following CH exposure in
mice is thought to be mostly mediated through pulmonary arterial cell migration. Cell migration
is a multifactorial process that requires changes in cell morphology and adhesion (47) and
depends on the intracellular calcium concentration (34). As demonstrated, TH17 cells are
increased following CH and produce IL-17A. We have demonstrate that IL-17A promotes the
migration of PASMC. We cultured PASMC with IL-17A and measured increased cell migration.
It has been shown that stimulation of TH17 cells with IL-17A results in increased production of
IL-6 (18). This may contribute to PASMC migration through a STAT3-dependent mechanism as
previously discussed. However, since we cultured PASMC with recombinant IL-17A in the
absence of TH17 cells, this provides strong evidence that IL-17A signaling alone promotes
PASMC migration, likely through IL-17A receptor downstream signaling events.
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The relative contribution of enhanced vasoconstriction versus remodeling to increased
pulmonary arterial pressure continues to be re-examined in the field. Originally believed to cause
inward narrowing of the vasculature lumen, remodeling was thought to be the cause of the
“fixed” components of PH. New evidence suggest however, that remodeling occurs in an
outward direction with little luminal encroachment. Studies have demonstrated that much of the
“fixed” remodeling was actually due to incomplete relaxation with the involvement of Rhokinase (23). Many of the studies examining a connection between inflammation and PH or PAH
focus on the potential of T cells to affect vascular remodeling, as mentioned above. The
possibility exists however, that T cells contribute to enhanced vasoconstriction, through the
release of cytokines that might lead to increased intracellular calcium or increased calcium
sensitivity. Elevated IL-17 levels are associated with hypertension and autoimmune diseases
associated with hypertension, including pre-eclampsia, systemic lupus erythematosus and
chronic allograft rejection (51). So far, the molecular mechanisms by which IL-17 contribute to
hypertension are largely unknown however a recent paper demonstrates that IL-17A increases
RhoA/Rho-kinase activity in vascular endothelial cells. Work from our group and others has
demonstrated that RhoA and its downstream effector, ROCK play a crucial role in a variety of
cellular functions in vascular smooth muscle cells, including smooth muscle contraction,
cytoskeletal rearrangement cell migration and cell proliferation (9, 46, 55, 56). From the work
done in endothelial cells, one might hypothesize that IL-17 may activate vascular smooth muscle
cell RhoA/Rho-kinase leading to increased myosin phosphatase phosphorylation, which may
contribute to enhanced vasoconstriction and calcium sensitization following CH.
We have shown that CH leads to an increase in perivascular TH17 cells, along with
increased IL-6 in the lung which is known to decrease endothelium-dependent relaxation of
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smooth muscle cells, along with enhancing smooth muscle contraction to agonists (39, 64). IL-6
from either the PASMC or the endothelium might be directly contributing to the inhibition of an
endothelium-dependent NO-mediated relaxation. To address whether IL-17 or IL-6 directly
promotes enhanced PASMC vasoconstriction constrictor studies must be performed. These
studies represent a potentially fruitful future direction of study, looking at the potential of T cells
and cytokines to affect pulmonary vasculature vasoconstriction.
A long-standing observation of PASMC exposed to CH was that these cells are
depolarized (61). Reduced K+ channel expression and activity are contributing factors to the
PASMC depolarization in CH-induced PH (53). As previously mentioned, STAT3 activation
through IL-6 has the potential to increase NFATc2 expression leading to decreased Kv1.5
expression and subsequent depolarization and calcium entry through voltage-gated calcium
channels, thus leading to enhanced vasoconstriction. Additionally, preliminary studies from our
lab, along with reports from other groups demonstrate that IL-6 trans-signaling can lead to acute
increases in intracellular calcium (58).
Our study, along with similar studies in models of PAH and systemic hypertension have
demonstrated that T cells contribute to vascular dysfunction. Much of the literature, including
our studies, focus on T cell-derived growth factors leading to vascular remodeling. Therefore,
vasoconstriction studies examining mechanisms of how T cells and their cytokines contribute to
vascular dysfunction are lacking from the literature. While few studies currently exist, more
work is clearly needed to elucidate mechanisms connecting inflammation with vascular
dysfunction. Given that T cells can secrete a large variety of cytokines, chemokines and growth
factors, there are many potential lines of investigation to follow. Using constrictor studies, one
could examine whether activated T cells directly contribute to vasoconstrictor reactivity. If so,
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how might T cells and their cytokines, chemokines and growth factors lead to enhanced
reactivity? Reactive oxygen species (ROS) are shown to play a crucial role in PH through the
activation of RhoA/ROCK (1). Many immune processes result in the production of ROS, mostly
intracellular to destroy pathogens. IL-17 leads to the recruitment of neutrophils, and neutrophils
are a key producer of ROS (35). Could ROS from IL-17-attracted neutrophils contribute to
enhanced vasoconstriction following CH?
It seems that T cells and their associated cytokines, chemokines and growth factors may
represent but a component of the two main contributing factors of CH-induced PH and eventual
cor pulmonale. It is likely, given the diversity and potential complexity of T-cell-derived
molecules, that inflammation from T cells contributes to both enhanced vasoconstriction through
mechanisms leading to increased intracellular calcium, along with more studied mechanisms of
vascular remodeling.
Patients with PH associated with chronic lung diseases are classified as having group 3
PH. For most patients with group 3 PH, the current recommendations for therapy are against
treatment with PAH-directed therapy because they have not been shown to provide significant
benefit (19, 43). The poor performance of PAH-directed therapy in group 3 patients is thought to
be due to the vasodilatory effects of these agents that may exacerbate ventilation-perfusion
abnormalities and worsen gas exchange in patients with lung disease (52). Therefore, the
recommended therapies are targeted at the underlying cause of the hypoxemia (5). Given the lack
of effective therapy for CH-induced PH, having multiple effective targets for treatment would
prove valuable. While broad-acting immunosuppressants are available, the more directed the
therapy, the less systemic side effects. Targeting TH17 cells directly with SR1001 (73), or
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disrupting IL-6 signaling to prevent PASMC migration and subsequent increased RVSP may
decrease morbidity and mortality from all group 3 PH, independent of the cause of hypoxemia.
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